



## Clinical trial results:

**A Phase 2, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the efficacy and safety of CAM-3001 in participants with rheumatoid arthritis (RA).**

### Summary

EudraCT number	2009-014735-20
Trial protocol	LV EE HU CZ LT PL BG
Global end of trial date	27 July 2012

### Results information

Result version number	v1 (current)
This version publication date	07 January 2017
First version publication date	07 January 2017

### Trial information

#### Trial identification

Sponsor protocol code	MI-CP219
-----------------------	----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01050998
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	MedImmune, LLC
Sponsor organisation address	Milstein Building, Granta Park, Cambridge, CB21 6GH United Kingdom, United Kingdom,
Public contact	Marius Albulescu, Associate Medical Director, MedImmune, LLC, +1 3013980000, albulescum@medimmune.com
Scientific contact	Marius Albulescu, Associate Medical Director, MedImmune, LLC, +1 3013980000, albulescum@medimmune.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 July 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 July 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Primary objectives of this study were to evaluate the safety, tolerability, and efficacy of multiple doses of mavrilimumab administered subcutaneous (SC) in participants with at least moderately active rheumatoid arthritis (RA).

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Participating participant signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 February 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 25
Country: Number of subjects enrolled	Czech Republic: 22
Country: Number of subjects enrolled	Estonia: 12
Country: Number of subjects enrolled	Japan: 51
Country: Number of subjects enrolled	Latvia: 9
Country: Number of subjects enrolled	Lithuania: 14
Country: Number of subjects enrolled	Poland: 29
Country: Number of subjects enrolled	Romania: 7
Country: Number of subjects enrolled	Russian Federation: 63
Country: Number of subjects enrolled	Ukraine: 28
Country: Number of subjects enrolled	Hungary: 24
Worldwide total number of subjects	284
EEA total number of subjects	142

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	247
From 65 to 84 years	37
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 516 participants were screened out of which 290 participants were randomized in the study. Six participants from one of the sites were excluded from ITT population prior to unblinding due to data integrity issues.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Mavrilimumab 10 milligram (mg)

Arm description:

Participants received Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Arm type	Experimental
Investigational medicinal product name	Mavrilimumab
Investigational medicinal product code	CAM-3001
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks.

<b>Arm title</b>	Mavrilimumab 30 mg
------------------	--------------------

Arm description:

Participants received Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Arm type	Experimental
Investigational medicinal product name	Mavrilimumab
Investigational medicinal product code	CAM-3001
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received Mavrilimumab (CAM-3001) 30 milligram (mg) injection subcutaneously every other week for 12 weeks.

<b>Arm title</b>	Mavrilimumab 50 mg
------------------	--------------------

Arm description:

Participants received Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Mavrilimumab
Investigational medicinal product code	CAM-3001
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.

<b>Arm title</b>	Mavrilimumab 100 mg
------------------	---------------------

Arm description:

Participants received Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Arm type	Experimental
Investigational medicinal product name	Mavrilimumab
Investigational medicinal product code	CAM-3001
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Participants received Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received Placebo Matched to Mavrilimumab injection subcutaneously every other week for 12 weeks.

Number of subjects in period 1	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg
Started	48	49	48
Completed	44	47	46
Not completed	4	2	2
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	1	-	1
Unspecified	3	2	1

Number of subjects in period 1	Mavrilimumab 100 mg	Placebo
Started	47	92

Completed	45	82
Not completed	2	10
Consent withdrawn by subject	1	3
Adverse event, non-fatal	-	2
Unspecified	1	5

## Baseline characteristics

### Reporting groups

Reporting group title	Mavrilimumab 10 milligram (mg)
Reporting group description: Participants received Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 30 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 50 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 100 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Placebo
Reporting group description: Participants received Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	

Reporting group values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg
Number of subjects	48	49	48
Age categorical Units: Subjects			
Adults (18- 64 Years)	42	43	42
Elderly (65-84 Years)	6	6	6
Age Continuous   Units: years			
arithmetic mean	52.2	51.1	52.7
standard deviation	± 11.9	± 12.1	± 10.3
Gender, Male/Female Units: participants			
Female	39	43	44
Male	9	6	4

Reporting group values	Mavrilimumab 100 mg	Placebo	Total
Number of subjects	47	92	284
Age categorical Units: Subjects			
Adults (18- 64 Years)	42	78	247
Elderly (65-84 Years)	5	14	37

Age Continuous   Units: years arithmetic mean standard deviation	50.1 ± 12.1	52.1 ± 12.8	-
Gender, Male/Female Units: participants			
Female	40	82	248
Male	7	10	36



## End points

### End points reporting groups

Reporting group title	Mavrilimumab 10 milligram (mg)
Reporting group description: Participants received Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 30 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 50 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Mavrilimumab 100 mg
Reporting group description: Participants received Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Reporting group title	Placebo
Reporting group description: Participants received Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Subject analysis set title	Placebo
Subject analysis set type	Safety analysis
Subject analysis set description: Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Subject analysis set title	Mavrilimumab 50 mg
Subject analysis set type	Safety analysis
Subject analysis set description: Participants received Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	
Subject analysis set title	Mavrilimumab 100mg
Subject analysis set type	Safety analysis
Subject analysis set description: Participants received Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.	

### Primary: Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85

End point title	Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85
-----------------	---

#### End point description:

DAS28 (CRP) calculated swollen joint count (SJC) and tender joint count (TJC) using the 28 joints, general health (GH) using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst), and CRP (milligram per Liter [mg/L]). Total score range: 0-9.4, higher score= more disease activity. DAS28 (CRP) less than (<) 3.2 = low disease activity, greater than or equal to (>=) 3.2 to 5.1 = moderate to high disease activity and <2.6=

remission. A Day 85 responder was defined as a participant who experienced more than 1.2 decrease from baseline in DAS28 (CRP) score at Day 85. The intent-to-treat (ITT) population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Primary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)	37.5	63.3	47.9	68.1

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)	32.6			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	= 0.578 <sup>[2]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	4.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.5
upper limit	22

Notes:

[1] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[2] - p-value was calculated using a two-tailed Fisher's exact test.

	Statistical Analysis 2
--	------------------------

<b>Statistical analysis title</b>	
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	< 0.001 <sup>[4]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	30.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.4
upper limit	46.3

Notes:

[3] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[4] - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[5]</sup>
P-value	= 0.099 <sup>[6]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	15.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	32.2

Notes:

[5] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[6] - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg

Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[7]</sup>
P-value	< 0.001 <sup>[8]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	35.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.8
upper limit	50.6

Notes:

[7] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[8] - p-value was calculated using a two-tailed Fisher's exact test.

### **Primary: Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region**

End point title	Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 85 by Region
-----------------	---

End point description:

DAS28 (CRP) calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst), and CRP (mg/L). Total score range: 0-9.4, higher score= more disease activity. DAS28 (CRP) <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. A Day 85 responder was defined as a participant who experienced more than 1.2 decrease from baseline in DAS28 (CRP) score at Day 85. DAS28 (CRP) response at Day 85 for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European Region (n=75, 39, 41, 39, 39)	41	61	51.3	66.7
Japanese Region (n=17, 9, 8, 9, 8)	22.2	75	33.3	75

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			

Units: percentage of participants				
number (not applicable)				
European Region (n=75, 39, 41, 39, 39)	34.7			
Japanese Region (n=17, 9, 8, 9, 8)	23.5			

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[9]</sup>
P-value	= 0.543 <sup>[10]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.9
upper limit	25.4

Notes:

[9] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[10] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[11]</sup>
P-value	= 0.011 <sup>[12]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	26.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.2
upper limit	43.6

Notes:

[11] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[12] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[13]</sup>
P-value	= 0.108 <sup>[14]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	35.5

Notes:

[13] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[14] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[15]</sup>
P-value	= 0.001 <sup>[16]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	32
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.5
upper limit	49

Notes:

[15] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[16] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[17]</sup>
P-value	= 1 <sup>[18]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-1.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.7
upper limit	35.7

Notes:

[17] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[18] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 6
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[19]</sup>
P-value	= 0.028 <sup>[20]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	51.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.2
upper limit	77

Notes:

[19] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[20] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[21]</sup>
P-value	= 0.661 <sup>[22]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	9.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.3
upper limit	46.9

Notes:

[21] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[22] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[23]</sup>
P-value	= 0.028 <sup>[24]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	51.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.2
upper limit	77

Notes:

[23] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[24] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

### **Primary: Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85**

End point title	Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85
-----------------	--

End point description:

DAS28 (ESR) calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst), and the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]). Total score range: 0-9.4, higher score = more disease activity. DAS28 (ESR) <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6 = remission. A Day 85 responder was defined as a participant who experienced more than 1.2 decrease from baseline in DAS28 (ESR) score at Day 85. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)	50	61.2	58.3	66

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			



Units: percentage of participants				
number (not applicable)	37			

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[25]</sup>
P-value	= 0.152 <sup>[26]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	30.3

Notes:

[25] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[26] - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[27]</sup>
P-value	= 0.008 <sup>[28]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	24.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	7
upper limit	40.3

Notes:

[27] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[28] - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[29]</sup>
P-value	= 0.02 <sup>[30]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	21.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.9
upper limit	37.8

Notes:

[29] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[30] - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[31]</sup>
P-value	= 0.002 <sup>[32]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	29
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.3
upper limit	45

Notes:

[31] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[32] - p-value was calculated using a two-tailed Fisher's exact test.

### **Primary: Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 by Region**

End point title	Percentage of Participants who Achieved Disease Activity Score of 28 Joints Using Erythrocyte Sedimentation Rate (DAS28 [ESR]) at Day 85 by Region
-----------------	--

End point description:

DAS28 (ESR) calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0=best, 10=worst), and the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]). Total score range: 0-9.4, higher score=more disease activity. DAS28 (ESR) <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. A Day 85 responder was defined as a participant who experienced more than 1.2 decrease from baseline in DAS28 (ESR) score at Day 85. DAS28 (ESR) response at Day 85 for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n"

signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Primary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European Region (n=75, 39, 41, 39, 39)	51.3	58.5	61.5	64.1
Japanese Region (n=17, 9, 8, 9, 8)	44.4	75	44.4	75

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
European Region (n=75, 39, 41, 39, 39)	41.3			
Japanese Region (n=17, 9, 8, 9, 8)	17.6			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[33]</sup>
P-value	= 0.328 <sup>[34]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	9.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	29.4

Notes:

[33] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[34] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[35]</sup>
P-value	= 0.084 <sup>[36]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	17.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	35.6

Notes:

[35] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[36] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[37]</sup>
P-value	= 0.049 <sup>[38]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	20.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	38.2

Notes:

[37] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[38] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg

Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[39]</sup>
P-value	= 0.03 <sup>[40]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	22.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.2
upper limit	40.7

Notes:

[39] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[40] - European region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[41]</sup>
P-value	= 0.188 <sup>[42]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	26.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	60.7

Notes:

[41] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[42] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[43]</sup>
P-value	= 0.01 <sup>[44]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	57.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	15.2
upper limit	81.8

Notes:

[43] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[44] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[45]</sup>
P-value	= 0.188 <sup>[46]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	26.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	60.7

Notes:

[45] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[46] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 8
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[47]</sup>
P-value	= 0.01 <sup>[48]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	57.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.2
upper limit	81.8

Notes:

[47] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[48] - Japanese region: p-value was calculated using a two-tailed Fisher's exact test.

## Primary: Percentage of Participants who Achieved DAS28 (CRP) Response by

## European League Against Rheumatism (EULAR) Category at Day 85

End point title	Percentage of Participants who Achieved DAS28 (CRP) Response by European League Against Rheumatism (EULAR) Category at Day 85 <sup>[49]</sup>
-----------------	---

End point description:

DAS28 (CRP) response by EULAR category were used to measure individual response as none, moderate, and good, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline more than ( $>$ )1.2 but less than ( $<$ ) 3.2; moderate response: change from baseline  $>1.2$  to more than or equal to ( $\geq$ ) 3.2 or less than or equal to ( $\leq$ ) 5.1 or change from baseline  $\geq 0.6$  to  $\leq 1.2$  to  $\geq 3.2$  to  $\leq 5.1$ ; no response: change from baseline  $<0.6$  or change from baseline  $\geq 0.6$  and  $\leq 1.2$  to  $>5.1$ . The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
No response	47.9	28.6	35.4	23.4
Moderate response	31.3	38.8	41.7	42.6
Good response	20.8	32.7	22.9	34

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
No response	51.1			
Moderate response	34.8			
Good response	14.1			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants who Achieved DAS28 (CRP) Response by European League Against Rheumatism (EULAR) Category at Day 85 by Region

End point title	Percentage of Participants who Achieved DAS28 (CRP) Response by European League Against Rheumatism (EULAR) Category at Day 85 by Region <sup>[50]</sup>
-----------------	---

End point description:

DAS28 (CRP) response by EULAR category were used to measure individual response as none, moderate, and good, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline more than ( $>$ )1.2 but less than ( $<$ ) 3.2; moderate response: change from baseline  $>1.2$  to more than or equal to ( $\geq$ ) 3.2 or less than or equal to ( $\leq$ ) 5.1 or change from baseline  $\geq 0.6$  to  $\leq 1.2$  to  $\geq 3.2$  to  $\leq 5.1$ ; no response: change from baseline  $<0.6$  or change from baseline  $\geq 0.6$  and  $\leq 1.2$  to  $>5.1$ . The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European: No response (n=75,39,41,39,39)	46.2	29.3	33.3	23.1
European: Moderate response (n=75,39,41,39,39)	33.3	41.5	41	46.2
European: Good response (n=75,39,41,39,39)	20.5	29.3	25.6	30.8
Japanese: No response (n=17,9,8,9,8)	55.6	25	44.4	25
Japanese: Moderate response (n=17,9,8,9,8)	22.2	25	44.4	25
Japanese: Good response (n=17,9,8,9,8)	22.2	50	11.1	50

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
European: No response (n=75,39,41,39,39)	49.3			
European: Moderate response (n=75,39,41,39,39)	36			
European: Good response (n=75,39,41,39,39)	14.7			
Japanese: No response (n=17,9,8,9,8)	58.8			
Japanese: Moderate response (n=17,9,8,9,8)	29.4			
Japanese: Good response (n=17,9,8,9,8)	11.8			



## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants who Achieved DAS28 (ESR) Response by European League Against Rheumatism (EULAR) Category at Day 85

End point title	Percentage of Participants who Achieved DAS28 (ESR) Response by European League Against Rheumatism (EULAR) Category at Day 85 <sup>[51]</sup>
-----------------	---

End point description:

DAS28 (CRP) response by EULAR category were used to measure individual response as none, moderate, and good, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline more than ( $>$ ) 1.2 but less than ( $<$ ) 3.2; moderate response: change from baseline  $>$  1.2 to more than or equal to ( $\geq$ ) 3.2 or less than or equal to ( $\leq$ ) 5.1 or change from baseline  $\geq$  0.6 to  $\leq$  1.2 to  $\geq$  3.2 to  $\leq$  5.1; no response: change from baseline  $<$  0.6 or change from baseline  $\geq$  0.6 and  $\leq$  1.2 to  $>$  5.1. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
No response	39.6	36.7	33.3	25.5
Moderate response	45.8	44.9	54.2	53.2
Good response	14.6	18.4	12.5	21.3

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
No response	55.4			
Moderate response	35.9			
Good response	8.7			

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants who Achieved DAS28 (ESR) Response by European League Against Rheumatism (EULAR) Category at Day 85 by Region

End point title	Percentage of Participants who Achieved DAS28 (ESR) Response by European League Against Rheumatism (EULAR) Category at Day 85 by Region <sup>[52]</sup>
-----------------	---

End point description:

DAS28 (CRP) response by EULAR category were used to measure individual response as none, moderate, and good, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline more than ( $>$ ) 1.2 but less than ( $<$ ) 3.2; moderate response: change from baseline  $>1.2$  to more than or equal to ( $\geq$ ) 3.2 or less than or equal to ( $\leq$ ) 5.1 or change from baseline  $\geq 0.6$  to  $\leq 1.2$  to  $\geq 3.2$  to  $\leq 5.1$ ; no response: change from baseline  $<0.6$  or change from baseline  $\geq 0.6$  and  $\leq 1.2$  to  $>5.1$ . The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[52] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European: No response (n=75,39,41,39,39)	38.5	39	33.3	28.2
European: Moderate response (n=75,39,41,39,39)	46.2	43.9	53.8	51.3
European: Good response (n=75,39,41,39,39)	15.4	17.1	12.8	20.5
Japanese: No response (n=17,9,8,9,8)	44.4	25	33.3	12.5
Japanese: Moderate response (n=17,9,8,9,8)	44.4	50	55.6	62.5
Japanese: Good response (n=17,9,8,9,8)	11.1	25	11.1	25

End point values	Placebo			
------------------	---------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
European: No response (n=75,39,41,39,39)	53.3			
European: Moderate response (n=75,39,41,39,39)	38.7			
European: Good response (n=75,39,41,39,39)	8			
Japanese: No response (n=17,9,8,9,8)	64.7			
Japanese: Moderate response (n=17,9,8,9,8)	23.5			
Japanese: Good response (n=17,9,8,9,8)	11.8			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

End point title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) <sup>[53]</sup> <sup>[54]</sup>
-----------------	--

End point description:

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up Day 169 that were absent before treatment or that worsened relative to pretreatment state. The safety population included all participants who received any dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Day 169 (follow-up)

Notes:

[53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: participants				
TEAEs	33	31	46	26
TESAEs	2	2	1	1

<b>End point values</b>	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: participants				
TEAEs	28			
TESAEs	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) <sup>[55]</sup> <sup>[56]</sup>
-----------------	--

End point description:

Vital sign assessments included blood pressure, pulse rate, temperature, and respiration rate. Vital signs abnormalities reported as TEAEs were reported. The safety population included all participants who received any dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Day 169 (follow-up)

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

<b>End point values</b>	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: participants				
Pyrexia	0	0	1	2
Hypertension	0	1	2	0

<b>End point values</b>	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			

Units: participants				
Pyrexia	0			
Hypertension	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Abnormal Electrocardiogram (ECG) Results

End point title	Number of Participants With Abnormal Electrocardiogram (ECG) Results <sup>[57][58]</sup>
-----------------	--

End point description:

12-lead ECG was recorded and corrected QT (QTc) interval was measured with the participant in a rested supine position for at least 10 minutes. Any ECG abnormality deemed clinically significant as per investigator's discretion were reported. The safety population included all participants who received any dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Day 169 (follow-up)

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: participants	1	0	0	0

End point values	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: participants	2			

## Statistical analyses

No statistical analyses for this end point

## Primary: Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity

**(FVC) at Day 85**

End point title	Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Day 85 <sup>[59]</sup> <sup>[60]</sup>
-----------------	---

End point description:

FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	46	47	47	87
Units: liters				
arithmetic mean (standard deviation)				
FEV1	2.877 (± 0.821)	2.949 (± 0.722)	2.793 (± 0.69)	2.73 (± 0.764)
FVC	3.582 (± 0.967)	3.667 (± 0.882)	3.499 (± 0.766)	3.439 (± 0.949)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: liters				
arithmetic mean (standard deviation)				
FEV1	2.701 (± 0.489)			
FVC	3.37 (± 0.527)			

**Statistical analyses**

No statistical analyses for this end point

**Primary: Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Day 85 by Region**

End point title	Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital
-----------------	--

## End point description:

FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FEV1 and FVC at Day 85 for the European and Japanese regions were reported. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

## Notes:

[61] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	46	47	47	87
Units: liters				
arithmetic mean (standard deviation)				
European: FEV1 (n=71,37,39,40,39)	2.902 (± 0.81)	3.042 (± 0.745)	2.848 (± 0.699)	2.811 (± 0.79)
European: FVC (n=71,37,39,40,39)	3.632 (± 0.948)	3.779 (± 0.917)	3.553 (± 0.772)	3.537 (± 0.996)
Japanese: FEV1 (n=16,9,8,9,8)	2.774 (± 0.908)	2.493 (± 0.354)	2.52 (± 0.616)	2.367 (± 0.51)
Japanese: FVC (n=16,9,8,9,8)	3.378 (± 1.076)	3.119 (± 0.37)	3.235 (± 0.725)	3.005 (± 0.534)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: liters				
arithmetic mean (standard deviation)				
European: FEV1 (n=71,37,39,40,39)	2.698 (± 0.501)			
European: FVC (n=71,37,39,40,39)	3.355 (± 0.537)			
Japanese: FEV1 (n=16,9,8,9,8)	2.712 (± 0.457)			
Japanese: FVC (n=16,9,8,9,8)	3.434 (± 0.505)			

## Statistical analyses

No statistical analyses for this end point

### Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Day 85

End point title	Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Day 85 <sup>[63]</sup> <sup>[64]</sup>
-----------------	---

End point description:

FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. The safety population included all participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure at the specified time point for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Day 85

Notes:

[63] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: liters				
arithmetic mean (standard deviation)				
Baseline: FEV1 (n=87,43,45,49,48)	2.788 (± 0.773)	2.99 (± 0.765)	2.79 (± 0.77)	2.76 (± 0.43)
Change at Day 85: FEV1 (n=87,46,47,49,47)	0.044 (± 0.231)	0.016 (± 0.196)	-0.039 (± 0.234)	-0.059 (± 0.249)
Baseline: FVC (n=87,43,45,49,48)	3.486 (± 0.963)	3.759 (± 0.868)	3.456 (± 0.948)	3.409 (± 0.496)
Change at Day 85: FVC (n=87,46,47,49,47)	0.048 (± 0.243)	-0.013 (± 0.239)	-0.012 (± 0.301)	-0.039 (± 0.496)

End point values	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: liters				
arithmetic mean (standard deviation)				
Baseline: FEV1 (n=87,43,45,49,48)	2.831 (± 0.681)			
Change at Day 85: FEV1 (n=87,46,47,49,47)	-0.049 (± 0.221)			
Baseline: FVC (n=87,43,45,49,48)	3.506 (± 0.804)			



Change at Day 85: FVC (n=87,46,47,49,47)	-0.017 ( $\pm$ 0.218)			
---	--------------------------	--	--	--

## Statistical analyses

No statistical analyses for this end point

## Primary: Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85

End point title	Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85 <sup>[65]</sup> <sup>[66]</sup>
-----------------	---

End point description:

DLCO is a pulmonary function test that measures the partial pressure difference between inspired and expired carbon monoxide. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[65] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	46	47	47	87
Units: percent diffusion capacity				
arithmetic mean (standard deviation)	95 ( $\pm$ 16.2)	95 ( $\pm$ 15.1)	89.3 ( $\pm$ 12)	91.7 ( $\pm$ 16.7)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: percent diffusion capacity				
arithmetic mean (standard deviation)	95 ( $\pm$ 15.7)			

## Statistical analyses

No statistical analyses for this end point

**Primary: Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85 by Region**

End point title	Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85 by Region <sup>[67]</sup> <sup>[68]</sup>
-----------------	---

End point description:

DLCO is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. DLCO% for the European and Japanese regions were reported. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[67] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	46	47	47	87
Units: percent diffusion capacity				
arithmetic mean (standard deviation)				
European region: (n=71,37,39,40,39)	96 (± 16.9)	94 (± 15.2)	88.6 (± 10.7)	90.4 (± 16.5)
Japanese region (n=16,9,8,9,8)	91 (± 13.3)	100.1 (± 14.6)	93 (± 17.2)	97.6 (± 16.9)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: percent diffusion capacity				
arithmetic mean (standard deviation)				
European region: (n=71,37,39,40,39)	94.8 (± 16.5)			
Japanese region (n=16,9,8,9,8)	96 (± 12.6)			

**Statistical analyses**

No statistical analyses for this end point

**Primary: Change from Baseline in Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85**

End point title	Change from Baseline in Diffusing Capacity for Carbon Monoxide (DLCO) at Day 85 <sup>[69]</sup> <sup>[70]</sup>
-----------------	---

End point description:

DLCO is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. The safety population included all participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure at the specified time point for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Day 85

Notes:

[69] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: percent diffusion capacity				
arithmetic mean (standard deviation)				
Baseline (n=86,40,45,49,48)	96.3 (± 17.7)	93.7 (± 15.5)	91.5 (± 12.5)	97.5 (± 14.8)
Change at Day 85 (n=87,46,47,49,47)	-3.1 (± 17.3)	0.4 (± 11.1)	0.1 (± 14.3)	-2.5 (± 10.8)

End point values	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percent diffusion capacity				
arithmetic mean (standard deviation)				
Baseline (n=86,40,45,49,48)	92.5 (± 13.7)			
Change at Day 85 (n=87,46,47,49,47)	-3.7 (± 11.3)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Dyspnea Score at Day 85

End point title	Dyspnea Score at Day 85 <sup>[71][72]</sup>
-----------------	---

End point description:

Modified Borg dyspnea scale is a validated participant reported outcome assessing participant's perceived difficulty in breathing (dyspnea). The scale ranges from 0 (nothing at all) to 10 (maximal difficulty). Higher scores indicate greater difficulty in breathing. The safety population included all participants who received any dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[71] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	47	89
Units: units on a scale				
arithmetic mean (standard deviation)	0.13 (± 0.38)	0.35 (± 0.7)	0.35 (± 0.59)	0.25 (± 0.48)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: units on a scale				
arithmetic mean (standard deviation)	0.15 (± 0.44)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Change from Baseline in Dyspnea Score at Day 85

End point title	Change from Baseline in Dyspnea Score at Day 85 <sup>[73]</sup> <sup>[74]</sup>
-----------------	---

End point description:

Modified Borg dyspnea scale is a validated participant reported outcome assessing participant's perceived difficulty in breathing (dyspnea). The scale ranges from 0 (nothing at all) to 10 (maximal difficulty). Higher scores indicate greater difficulty in breathing. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Day 85

Notes:

[73] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[74] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all

the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline (n=96,48,49,49,48)	0.26 (± 0.88)	0.26 (± 0.59)	0.29 (± 0.58)	0.19 (± 0.49)
Change at Day 85 (n=89,45,47,49,47)	-0.14 (± 0.62)	0.1 (± 0.44)	-0.06 (± 0.53)	-0.04 (± 0.35)

End point values	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline (n=96,48,49,49,48)	0.32 (± 0.59)			
Change at Day 85 (n=89,45,47,49,47)	0.02 (± 0.56)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Categorized Dyspnea Score at Day 85

End point title	Categorized Dyspnea Score at Day 85 <sup>[75]</sup> <sup>[76]</sup>
End point description:	
Modified Borg dyspnea scale is a validated participant reported outcome assessing participant's perceived difficulty in breathing (dyspnea). The scale ranges from 0 (nothing at all) to 10 (maximal difficulty). Higher scores indicate greater difficulty in breathing. The modified BORG dyspnea scale was categorized as - no/slight (0 to 2), moderate (3 and 4), severe (5 and 6) and very severe breathlessness (7 and above). The safety population included all participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure at the specified time point for each arm, respectively.	
End point type	Primary
End point timeframe:	
Day 85	

Notes:

[75] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[76] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	47	89
Units: participants				
No/Slight breathlessness	45	45	46	89
Moderate breathlessness	0	2	1	0
Severe breathlessness	0	0	0	0
Very severe breathlessness	0	0	0	0

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: participants				
No/Slight breathlessness	49			
Moderate breathlessness	0			
Severe breathlessness	0			
Very severe breathlessness	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Oxygen Saturation Level at Day 85

End point title	Oxygen Saturation Level at Day 85 <sup>[77]</sup> <sup>[78]</sup>
-----------------	---

End point description:

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[77] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	47	88
Units: percent saturation				
arithmetic mean (standard deviation)	97.6 (± 1.3)	97.7 (± 1.3)	97.3 (± 1.5)	97.5 (± 1.2)

End point values	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: percent saturation				
arithmetic mean (standard deviation)	97.2 (± 1.8)			

## Statistical analyses

No statistical analyses for this end point

## Primary: Oxygen Saturation Level at Day 85 by Region

End point title	Oxygen Saturation Level at Day 85 by Region <sup>[79]</sup> <sup>[80]</sup>
-----------------	---

End point description:

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood. Oxygen saturation for the European and Japanese regions were reported. The safety population included all participants who received any dose of investigational product. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Day 85

Notes:

[79] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[80] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	47	88
Units: percent saturation				
arithmetic mean (standard deviation)				
European region: (n=72,36,39,40,39)	97.6 (± 1.3)	97.6 (± 1.3)	97.3 (± 1.6)	97.5 (± 1.3)
Japanese region: (n=16,9,8,9,8)	97.4 (± 1)	98.4 (± 1.1)	97.3 (± 1.3)	97.6 (± 0.9)

<b>End point values</b>	Mavrilimumab 50 mg			
Subject group type	Subject analysis set			
Number of subjects analysed	49			
Units: percent saturation				
arithmetic mean (standard deviation)				
European region: (n=72,36,39,40,39) Japanese region: (n=16,9,8,9,8)	97.2 (± 2) 97.4 (± 0.7)			

## Statistical analyses

No statistical analyses for this end point

### Primary: Change from Baseline in Oxygen Saturation Level at Day 85

End point title	Change from Baseline in Oxygen Saturation Level at Day
-----------------	--

End point description:

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood. The safety population included all participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure at the specified time point for each arm, respectively.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Day 85

Notes:

[81] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[82] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

<b>End point values</b>	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: percent saturation				
arithmetic mean (standard deviation)				
Baseline (n=96,48,49,49,48)	97.8 (± 1.6)	97.6 (± 1.2)	97.5 (± 1.3)	97.6 (± 1.4)
Change at Day 85 (n=88,45,47,49,47)	-0.2 (± 1.5)	0.1 (± 1.4)	0 (± 1.5)	-0.3 (± 1.9)

<b>End point values</b>	Mavrilimumab 100mg			
-------------------------	-----------------------	--	--	--



Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percent saturation				
arithmetic mean (standard deviation)				
Baseline (n=96,48,49,49,48)	97.2 (± 1.7)			
Change at Day 85 (n=88,45,47,49,47)	0.1 (± 2.1)			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Participants with Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs) <sup>[83][84]</sup>
-----------------	---

End point description:

Any medically significant change in laboratory evaluations were recorded as adverse events. Following parameters were analyzed for laboratory examination: hematology (haemoglobin, reticulocytes, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, mean corpuscular volume, mean corpuscular haemoglobin concentration); serum chemistry (creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, gamma glutamyl transferase, CRP, ESR, albumin, total cholesterol, triglycerides, rheumatoid factor and anti-cyclic citrullinated peptide antibodies); urinalysis (albumin, glucose, protein, blood, nitrite). The safety population included all participants who received any dose of investigational product.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Day 169 (follow-up)

Notes:

[83] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: participants				
Blood and lymphatic system disorders	3	3	10	3
Hepatic abnormality	5	3	3	2
Blood cholesterol increased	0	0	0	1
Blood triglycerides increased	0	0	1	0
Hypercholesterolemia	1	1	1	1
Hyperglycemia	0	0	1	1
Urinalysis abnormalities	0	3	3	1

<b>End point values</b>	Mavrimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: participants				
Blood and lymphatic system disorders	4			
Hepatic abnormality	3			
Blood cholesterol increased	0			
Blood triglycerides increased	0			
Hypercholesterolemia	0			
Hyperglycemia	0			
Urinalysis abnormalities	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in DAS28 (CRP) and DAS28 (ESR) at Day 85

End point title	Change from Baseline in DAS28 (CRP) and DAS28 (ESR) at Day 85
-----------------	---

End point description:

DAS28 calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 85

<b>End point values</b>	Mavrimumab 10 milligram (mg)	Mavrimumab 30 mg	Mavrimumab 50 mg	Mavrimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: units on a scale				
arithmetic mean (standard error)				
DAS28(CRP): Baseline (n=92,48,49,48,47)	5.24 (± 0.16)	5.42 (± 0.139)	5.14 (± 0.146)	5.34 (± 0.115)
DAS28(CRP): Change at Day 85 (n=84,45,46,48,46)	-1.27 (± 0.166)	-1.63 (± 0.163)	-1.32 (± 0.162)	-1.7 (± 0.165)
DAS28(ESR): Baseline: (n=92,48,49,48,47)	6.06 (± 0.165)	6.31 (± 0.145)	5.98 (± 0.163)	6.06 (± 0.119)

DAS28(ESR): Change at Day 85 (n=85,45,47,48,46)	-1.39 ( $\pm$ 0.172)	-1.8 ( $\pm$ 0.17)	-1.46 ( $\pm$ 0.168)	-1.84 ( $\pm$ 0.172)
--	----------------------	--------------------	----------------------	----------------------

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: units on a scale				
arithmetic mean (standard error)				
DAS28(CRP): Baseline (n=92,48,49,48,47)	5.43 ( $\pm$ 0.11)			
DAS28(CRP): Change at Day 85 (n=84,45,46,48,46)	-0.97 ( $\pm$ 0.12)			
DAS28(ESR): Baseline: (n=92,48,49,48,47)	6.18 ( $\pm$ 0.118)			
DAS28(ESR): Change at Day 85 (n=85,45,47,48,46)	-1.04 ( $\pm$ 0.125)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[85]</sup>
P-value	= 0.137
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.71
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.205

Notes:

[85] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg

Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[86]</sup>
P-value	= 0.001
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.07
upper limit	-0.27
Variability estimate	Standard error of the mean
Dispersion value	0.202

Notes:

[86] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[87]</sup>
P-value	= 0.08
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.75
upper limit	0.04
Variability estimate	Standard error of the mean
Dispersion value	0.201

Notes:

[87] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[88]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.74

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.14
upper limit	-0.33
Variability estimate	Standard error of the mean
Dispersion value	0.204

Notes:

[88] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[89]</sup>
P-value	= 0.107
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.34

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.76
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.212

Notes:

[89] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[90]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.76

Confidence interval

level	95 %
sides	2-sided
lower limit	-1.17
upper limit	-0.35
Variability estimate	Standard error of the mean
Dispersion value	0.21

Notes:

[90] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 7
Statistical analysis description:	
Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[91]</sup>
P-value	= 0.046
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.83
upper limit	-0.01
Variability estimate	Standard error of the mean
Dispersion value	0.209

Notes:

[91] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[92]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.22
upper limit	-0.38
Variability estimate	Standard error of the mean
Dispersion value	0.212

Notes:

[92] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Change from Baseline in DAS28 (CRP) and DAS28 (ESR) at Day 85 by Region

End point title	Change from Baseline in DAS28 (CRP) and DAS28 (ESR) at Day 85 by Region
-----------------	---

End point description:

DAS28 calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. DAS28 (CRP) and DAS28 (ESR) for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: units on a scale				
arithmetic mean (standard error)				
European: DAS28(CRP): Baseline (n=75,39,41,39,39)	5.3 (± 0.172)	5.48 (± 0.154)	5.33 (± 0.155)	5.41 (± 0.111)
European: DAS28(CRP): Day 85 (n=68,36,38,39,38)	-1.4 (± 0.187)	-1.55 (± 0.181)	-1.43 (± 0.181)	-1.7 (± 0.183)
Japanese: DAS28(CRP): Baseline (n=17,9,8,9,8)	5 (± 0.427)	5.12 (± 0.306)	4.32 (± 0.268)	5.04 (± 0.413)
Japanese: DAS28(CRP): Day 85 (n=16,9,8,9,8)	-0.73 (± 0.358)	-2.04 (± 0.381)	-0.89 (± 0.361)	-1.71 (± 0.38)
European: DAS28(ESR): Baseline (n=75,39,41,39,39)	6.1 (± 0.18)	6.36 (± 0.163)	6.23 (± 0.159)	6.12 (± 0.118)
European: DAS28(ESR): Day 85 (n=69,36,39,39,38)	-1.51 (± 0.196)	-1.76 (± 0.19)	-1.53 (± 0.19)	-1.85 (± 0.193)
Japanese: DAS28(ESR): Baseline (n=17,9,8,9,8)	5.87 (± 0.426)	6.05 (± 0.309)	4.93 (± 0.379)	5.78 (± 0.404)
Japanese: DAS28(ESR): Day 85 (n=16,9,8,9,8)	-0.83 (± 0.359)	-1.99 (± 0.382)	-1.24 (± 0.362)	-1.78 (± 0.38)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: units on a scale				
arithmetic mean (standard error)				
European: DAS28(CRP): Baseline (n=75,39,41,39,39)	5.58 (± 0.117)			
European: DAS28(CRP): Day 85 (n=68,36,38,39,38)	-1 (± 0.133)			
Japanese: DAS28(CRP): Baseline (n=17,9,8,9,8)	4.75 (± 0.242)			
Japanese: DAS28(CRP): Day 85 (n=16,9,8,9,8)	-0.85 (± 0.281)			
European: DAS28(ESR): Baseline (n=75,39,41,39,39)	6.36 (± 0.124)			

European: DAS28(ESR): Day 85 (n=69,36,39,39,38)	-1.12 ( $\pm$ 0.14)			
Japanese: DAS28(ESR): Baseline (n=17,9,8,9,8)	5.38 ( $\pm$ 0.248)			
Japanese: DAS28(ESR): Day 85 (n=16,9,8,9,8)	-0.74 ( $\pm$ 0.276)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[93]</sup>
P-value	= 0.086
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.85
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.23

Notes:

[93] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[94]</sup>
P-value	= 0.016
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.99
upper limit	-0.1
Variability estimate	Standard error of the mean
Dispersion value	0.225



Notes:

[94] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[95]</sup>
P-value	= 0.059
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	0.02
Variability estimate	Standard error of the mean
Dispersion value	0.225

Notes:

[95] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[96]</sup>
P-value	= 0.002
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.14
upper limit	-0.25
Variability estimate	Standard error of the mean
Dispersion value	0.227

Notes:

[96] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[97]</sup>
P-value	= 0.107
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	0.09
Variability estimate	Standard error of the mean
Dispersion value	0.241

Notes:

[97] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[98]</sup>
P-value	= 0.007
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.11
upper limit	-0.18
Variability estimate	Standard error of the mean
Dispersion value	0.236

Notes:

[98] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
European region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg

Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[99]</sup>
P-value	= 0.084
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.88
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.236

Notes:

[99] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

European region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[100]</sup>
P-value	= 0.002
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.26
Variability estimate	Standard error of the mean
Dispersion value	0.238

Notes:

[100] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 9
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[101]</sup>
P-value	= 0.785
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	0.12

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.78
upper limit	1.02
Variability estimate	Standard error of the mean
Dispersion value	0.447

Notes:

[101] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 10
-----------------------------------	-------------------------

Statistical analysis description:

Japanese region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[102]</sup>
P-value	= 0.014
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-1.19

Confidence interval

level	95 %
sides	2-sided
lower limit	-2.13
upper limit	-0.26
Variability estimate	Standard error of the mean
Dispersion value	0.465

Notes:

[102] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 11
-----------------------------------	-------------------------

Statistical analysis description:

Japanese region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[103]</sup>
P-value	= 0.931
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.04

Confidence interval

level	95 %
sides	2-sided
lower limit	-0.94
upper limit	0.86
Variability estimate	Standard error of the mean
Dispersion value	0.448

Notes:

[103] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 12
Statistical analysis description:	
Japanese region: Analysis reported for change from baseline in DAS28 (CRP) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[104]</sup>
P-value	= 0.07
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	0.07
Variability estimate	Standard error of the mean
Dispersion value	0.465

Notes:

[104] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 13
Statistical analysis description:	
Japanese region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[105]</sup>
P-value	= 0.854
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.99
upper limit	0.82
Variability estimate	Standard error of the mean
Dispersion value	0.449

Notes:

[105] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 14
Statistical analysis description:	
Japanese region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[106]</sup>
P-value	= 0.011
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-1.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.19
upper limit	-0.31
Variability estimate	Standard error of the mean
Dispersion value	0.468

Notes:

[106] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 15
Statistical analysis description:	
Japanese region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[107]</sup>
P-value	= 0.271
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.448

Notes:

[107] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 16
Statistical analysis description:	
Japanese region: Analysis reported for change from baseline in DAS28 (ESR) at Day 85. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg

Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[108]</sup>
P-value	= 0.031
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	-1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.97
upper limit	-0.1
Variability estimate	Standard error of the mean
Dispersion value	0.465

Notes:

[108] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

### Secondary: Percentage of Participants who Achieved DAS28 (CRP) and DAS28 (ESR) Remission at Day 85

End point title	Percentage of Participants who Achieved DAS28 (CRP) and DAS28 (ESR) Remission at Day 85
-----------------	---

End point description:

DAS28 calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. Remission was defined as less than 2.6 DAS28 (ESR) or DAS28 (CRP) score. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants number (not applicable)				
DAS28(CRP)	14.6	22.4	18.8	23.4
DAS28(ESR)	6.3	8.2	8.3	6.4

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				

number (not applicable)				
DAS28(CRP)	7.6			
DAS28(ESR)	3.3			

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (CRP): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[109]</sup>
P-value	= 0.238
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	20.5

Notes:

[109] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (CRP): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[110]</sup>
P-value	= 0.017
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	14.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	29.7

Notes:

[110] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (CRP): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was



dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[111]</sup>
P-value	= 0.09
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	11.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	25.4

Notes:

[111] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (CRP): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[112]</sup>
P-value	= 0.015
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	15.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.9
upper limit	31

Notes:

[112] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (ESR): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[113]</sup>
P-value	= 0.412
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	14

Notes:

[113] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (ESR): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[114]</sup>
P-value	= 0.237
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	4.9

Confidence interval

level	95 %
sides	2-sided
lower limit	-2.9
upper limit	16.4

Notes:

[114] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (ESR): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[115]</sup>
P-value	= 0.231
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	5.1

Confidence interval

level	95 %
sides	2-sided
lower limit	-2.8
upper limit	16.8

Notes:

[115] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

DAS28 (ESR): p-value was calculated using a two-tailed Fisher's exact test. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[116]</sup>
P-value	= 0.406
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	14.4

Notes:

[116] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

**Secondary: Percentage of Participants who Achieved DAS28 (CRP) and DAS28 (ESR) Remission at Day 85 by Region**

End point title	Percentage of Participants who Achieved DAS28 (CRP) and DAS28 (ESR) Remission at Day 85 by Region
-----------------	---

End point description:

DAS28 calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. Remission was defined as less than 2.6 DAS28 (ESR) or DAS28 (CRP) score. DAS28 (CRP) and DAS28 (ESR) for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European: DAS28(CRP):(n=75,39,41,39,39)	15.4	17.1	17.9	23.1
European: DAS28(ESR):(n=75,39,41,39,39)	7.7	9.8	7.7	7.7
Japanese: DAS28(CRP) (n=17,9,8,9,8)	11.1	50	22.2	25
Japanese: DAS28(ESR) (n=17,9,8,9,8)	0	0	11.1	0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
European: DAS28(CRP): (n=75,39,41,39,39)	6.7			
European: DAS28(ESR): (n=75,39,41,39,39)	1.3			
Japanese: DAS28(CRP) (n=17,9,8,9,8)	11.8			
Japanese: DAS28(ESR) (n=17,9,8,9,8)	11.8			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[117]</sup>
P-value	= 0.182 <sup>[118]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	24.4

Notes:

[117] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[118] - European region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[119]</sup>
P-value	= 0.11 <sup>[120]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	10.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	25.5

Notes:

[119] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[120] - European region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[121]</sup>
P-value	= 0.104 <sup>[122]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	11.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	26.9

Notes:

[121] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[122] - European region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[123]</sup>
P-value	= 0.016 <sup>[124]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	16.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.5
upper limit	32.7

Notes:

[123] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[124] - European region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	235
Analysis specification	Pre-specified
Analysis type	other <sup>[125]</sup>
P-value	= 0.115 <sup>[126]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	19.3

Notes:

[125] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[126] - European region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[127]</sup>
P-value	= 0.052 <sup>[128]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	8.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	21.6

Notes:

[127] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[128] - European region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg v Mavrilimumab 100 mg
-------------------	---

Number of subjects included in analysis	235
Analysis specification	Pre-specified
Analysis type	other <sup>[129]</sup>
P-value	= 0.115 <sup>[130]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	19.3

Notes:

[129] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[130] - European region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	235
Analysis specification	Pre-specified
Analysis type	other <sup>[131]</sup>
P-value	= 0.115 <sup>[132]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	19.3

Notes:

[131] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[132] - European region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 9
-----------------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[133]</sup>
P-value	= 1 <sup>[134]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-0.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	34.8

Notes:

[133] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[134] - Japanese region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 10
-----------------------------------	-------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[135]</sup>
P-value	= 0.059 <sup>[136]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	38.2

Confidence interval

level	95 %
sides	2-sided
lower limit	1.6
upper limit	71.2

Notes:

[135] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[136] - Japanese region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 11
-----------------------------------	-------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[137]</sup>
P-value	= 0.591 <sup>[138]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	10.5

Confidence interval

level	95 %
sides	2-sided
lower limit	-18.2
upper limit	46.2

Notes:

[137] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[138] - Japanese region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 12
-----------------------------------	-------------------------



Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[139]</sup>
P-value	= 0.57 <sup>[140]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	13.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.6
upper limit	51.4

Notes:

[139] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[140] - Japanese region (DAS28 [CRP]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 13
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[141]</sup>
P-value	= 0.529 <sup>[142]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35
upper limit	22.7

Notes:

[141] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[142] - Japanese region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 14
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[143]</sup>
P-value	= 1 <sup>[144]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.5
upper limit	22.6

Notes:

[143] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[144] - Japanese region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 15
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[145]</sup>
P-value	= 1 <sup>[146]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	34.8

Notes:

[145] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[146] - Japanese region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 16
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[147]</sup>
P-value	= 1 <sup>[148]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.5
upper limit	22.6

Notes:

[147] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

[148] - Japanese region (DAS28 [ESR]): p-value was calculated using a two-tailed Fisher's exact test.

## Secondary: Time to Onset for DAS28 (CRP) and DAS (ESR) Response and Remission

End point title	Time to Onset for DAS28 (CRP) and DAS (ESR) Response and Remission
End point description: DAS28 calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 <3.2 = low disease activity, >=3.2 to 5.1 = moderate to high disease activity and <2.6= remission. Response was defined as 1.2 decrease from baseline in DAS28 (CRP) or DAS28 (ESR) score. Remission was defined as less than 2.6 DAS28 (CRP) or DAS28 (ESR) score. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.	
End point type	Secondary
End point timeframe: Baseline up to Day 169 (follow-up)	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: days				
median (confidence interval 95%)				
DAS28 (CRP) Response	84 (43 to 99999)	43 (29 to 58)	71 (42 to 89)	42 (29 to 45)
DAS28 (CRP) Remission	99999 (-99999 to 99999)	99999 (99999 to 99999)	99999 (-99999 to 99999)	99999 (-99999 to 99999)
DAS28 (ESR) Response	58 (43 to 86)	30 (29 to 43)	57 (29 to 71)	29 (28 to 42)
DAS28 (ESR) Remission	99999 (-99999 to 99999)	99999 (-99999 to 99999)	99999 (-99999 to 99999)	99999 (-99999 to 99999)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: days				
median (confidence interval 95%)				
DAS28 (CRP) Response	88 (57 to 88)			
DAS28 (CRP) Remission	99999 (-99999 to 99999)			
DAS28 (ESR) Response	85 (57 to 88)			
DAS28 (ESR) Remission	99999 (-99999 to 99999)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.604
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.145
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)

Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.282
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.047
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

## **Secondary: Time to Onset for DAS28 (CRP) and DAS (ESR) Response and Remission by Region**

End point title	Time to Onset for DAS28 (CRP) and DAS (ESR) Response and Remission by Region
-----------------	--

**End point description:**

DAS28 calculated SJC and TJC using the 28 joints,GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0=best,10=worst) and CRP(mg/L) for DAS28(CRP)orESR(mm/hour) for DAS28(ESR). Total score range:0-9.4, higher score=more disease activity.DAS28<3.2=low disease activity,>=3.2 to 5.1=moderate to high disease activity and<2.6=remission.Response was defined as 1.2 decrease from baseline in DAS28(CRP)orDAS28(ESR) score. Remission was defined as <2.6 DAS28(CRP)orDAS28(ESR) score. Time to response for DAS28(CRP) and DAS28(ESR) by region were reported. Time to remission for DAS28(CRP) and DAS28(ESR) by region were not analyzed because time to remission for the overall study population could not be achieved. The ITT population was analysed and six participants were excluded for data integrity issues. Here "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Day 169 (follow-up)

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: days				
median (confidence interval 95%)				
European: DAS28 (CRP) Response (n=75,39,41,39,39)	43 (43 to 99999)	43 (42 to 71)	50 (29 to 89)	42 (29 to 57)
Japanese: DAS28 (CRP) Response (n=17,9,8,9,8)	99999 (-99999 to 99999)	22.5 (15 to 57)	87 (30 to 87)	37 (15 to 57)
European: DAS28 (ESR) Response (n=75,39,41,39,39)	57 (30 to 85)	42 (29 to 43)	52.5 (29 to 84)	29 (28 to 42)
Japanese: DAS28 (ESR) Response (n=17,9,8,9,8)	86 (57 to 86)	29 (15 to 44)	44.5 (29 to 99999)	30 (15 to 44)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: days				
median (confidence interval 95%)				
European: DAS28 (CRP) Response (n=75,39,41,39,39)	85 (57 to 88)			
Japanese: DAS28 (CRP) Response (n=17,9,8,9,8)	99999 (-99999 to 99999)			
European: DAS28 (ESR) Response (n=75,39,41,39,39)	71 (57 to 88)			
Japanese: DAS28 (ESR) Response (n=17,9,8,9,8)	99999 (-99999 to 99999)			

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
European region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.237
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
European region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
European region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.134
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Japanese region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.265
Method	Logrank

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

European region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 6

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.013
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 7

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.952
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 9

Statistical analysis description:

European region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.246
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 10



Statistical analysis description:

European region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 8

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.004
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 11

Statistical analysis description:

European region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.126
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 12

Statistical analysis description:

European region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg v Mavrilimumab 100 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 15

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.125
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 14

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 13

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.831
Method	Logrank

---

**Statistical analysis title**

Statistical Analysis 16

Statistical analysis description:

Japanese region: Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Logrank

---

**Secondary: Duration of DAS28 (CRP) and DAS28 (ESR) Response and Remission**

End point title	Duration of DAS28 (CRP) and DAS28 (ESR) Response and
-----------------	--

## End point description:

DAS28 calculated SJC and TJC using 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using numerical rating scale with 0=best, 10=worst) and CRP (mg/L) for DAS28 (CRP) or ESR (mm/hour) for DAS28 (ESR). Total score range: 0-9.4, higher score = more disease activity. DAS28 < 3.2 = low disease activity, >= 3.2 to 5.1 = moderate to high disease activity and < 2.6 = remission. Response defined as 1.2 decrease from baseline in DAS28 (CRP) or DAS28 (ESR) score. Remission defined as < 2.6 DAS28 (CRP) or DAS28 (ESR) score. Expected duration of response (DOR) calculated as response rate (in percentage) multiplied by mean DOR (in days) by using Weibull Model. Duration of DAS28 (CRP) and DAS28 (ESR) remission were not analyzed because very few participants achieved remission in the overall study population. ITT population (6 participants were excluded for data integrity issues). Here "n" signifies participants who were evaluable for this measure for specified parameter for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Day 169

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: Percentage of days				
number (not applicable)				
DAS28 (CRP) Response	42.19	81.89	54.8	83.07
DAS28 (ESR) Response	52.96	71.14	75.97	96.52

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: Percentage of days				
number (not applicable)				
DAS28 (CRP) Response	43.4			
DAS28 (ESR) Response	46.11			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
-------------------	--

Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[149]</sup>
P-value	= 0.486
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.69

Notes:

[149] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[150]</sup>
P-value	= 0.015
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.09
upper limit	2.18

Notes:

[150] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[151]</sup>
P-value	= 0.006
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.15
upper limit	2.36

Notes:

[151] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Analysis reported for DAS28 (ESR) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[152]</sup>
P-value	< 0.001
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	2.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.49
upper limit	2.93

Notes:

[152] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[153]</sup>
P-value	= 0.906
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.55

Notes:

[153] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg

Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[154]</sup>
P-value	< 0.001
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.31
upper limit	2.71

Notes:

[154] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[155]</sup>
P-value	= 0.272
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.91

Notes:

[155] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for DAS28 (CRP) response. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[156]</sup>
P-value	< 0.001
Method	Exponential,Weibull and Log normal model
Parameter estimate	Ratio of expected duration of response
Point estimate	1.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.34
upper limit	2.72

Notes:

[156] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

## Secondary: Percentage of Participants who Achieved American College of Rheumatology 20 (ACR20), ACR50 and ACR70 Responses at Day 85

End point title	Percentage of Participants who Achieved American College of Rheumatology 20 (ACR20), ACR50 and ACR70 Responses at Day 85
-----------------	--

End point description:

ACR20, ACR50, and ACR70, were defined as greater than or equal to ( $\geq$ ) 20 percent (%),  $\geq$ 50%, or  $\geq$ 70% improvement, respectively, in: swollen joint count and tender joint count and  $\geq$ 20%,  $\geq$ 50%, or  $\geq$ 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
ACR20	41.7	57.1	37.5	70.2
ACR50	20.8	30.6	16.7	34
ACR70	4.2	10.2	6.3	14.9

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
ACR20	37			
ACR50	12			
ACR70	5.4			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[157]</sup>
P-value	= 0.589 <sup>[158]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	4.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.1
upper limit	22

Notes:

[157] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[158] - ACR50: p-value was calculated using a two-tailed Fisher's exact test-

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[159]</sup>
P-value	= 0.032 <sup>[160]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	20.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	36.7

Notes:

[159] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[160] - ACR50: p-value was calculated using a two-tailed Fisher's exact test-

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[161]</sup>
P-value	= 1 <sup>[162]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	0.5



Confidence interval	
level	95 %
sides	2-sided
lower limit	-16
upper limit	18

Notes:

[161] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[162] - ACR50: p-value was calculated using a two-tailed Fisher's exact test-

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[163]</sup>
P-value	< 0.001 <sup>[164]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	33.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.6
upper limit	48.6

Notes:

[163] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[164] - ACR50: p-value was calculated using a two-tailed Fisher's exact test-

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[165]</sup>
P-value	= 0.212 <sup>[166]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	8.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	23.6

Notes:

[165] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[166] - ACR50: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[167]</sup>
P-value	= 0.011 <sup>[168]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	18.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.8
upper limit	34

Notes:

[167] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[168] - ACR50: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[169]</sup>
P-value	= 0.446 <sup>[170]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	4.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	19.1

Notes:

[169] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[170] - ACR50: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 8
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[171]</sup>
P-value	= 0.003 <sup>[172]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	22.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	7.6
upper limit	37.8

Notes:

[171] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[172] - ACR50: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 9
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[173]</sup>
P-value	= 1 <sup>[174]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.9
upper limit	9.7

Notes:

[173] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[174] - ACR70: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 10
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[175]</sup>
P-value	= 0.317 <sup>[176]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	4.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	17.5

Notes:

[175] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[176] - ACR70: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 11
-----------------------------------	-------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[177]</sup>
P-value	= 1 <sup>[178]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.2
upper limit	12.1

Notes:

[177] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[178] - ACR70: p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 12
-----------------------------------	-------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[179]</sup>
P-value	= 0.106 <sup>[180]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	23.5

Notes:

[179] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[180] - ACR70: p-value was calculated using a two-tailed Fisher's exact test.

### **Secondary: Percentage of Participants who Achieved American College of Rheumatology 20 (ACR20), ACR50 and ACR70 Responses at Day 85 by Region**

End point title	Percentage of Participants who Achieved American College of Rheumatology 20 (ACR20), ACR50 and ACR70 Responses at Day 85 by Region
-----------------	--

End point description:

ACR20, ACR50, and ACR70, were defined as  $\geq 20\%$ ,  $\geq 50\%$ , or  $\geq 70\%$  improvement, respectively, in: SJC and TJC and  $\geq 20\%$ ,  $\geq 50\%$ , or  $\geq 70\%$  improvement, respectively, in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. Data for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: percentage of participants				
number (not applicable)				
European: ACR20 (n=75,39,41,39,39)	41	56.1	41	69.2
Japanese: ACR20 (n=17,9,8,9,8)	44.4	62.5	22.2	75
European: ACR50 (n=75,39,41,39,39)	23.1	29.3	20.5	30.8
Japanese: ACR50 (n=17,9,8,9,8)	11.1	37.5	0	50
European: ACR70 (n=75,39,41,39,39)	5.1	9.8	7.7	17.9
Japanese: ACR70 (n=17,9,8,9,8)	0	12.5	0	0

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: percentage of participants				
number (not applicable)				
European: ACR20 (n=75,39,41,39,39)	40			
Japanese: ACR20 (n=17,9,8,9,8)	23.5			
European: ACR50 (n=75,39,41,39,39)	12			
Japanese: ACR50 (n=17,9,8,9,8)	11.8			
European: ACR70 (n=75,39,41,39,39)	4			
Japanese: ACR70 (n=17,9,8,9,8)	11.8			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[181]</sup>
P-value	= 1 <sup>[182]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.7
upper limit	20.4

Notes:

[181] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[182] - European region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[183]</sup>
P-value	= 0.12 <sup>[184]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	16.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	34.4

Notes:

[183] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001

[184] - European region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[185]</sup>
P-value	= 1 <sup>[186]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.7
upper limit	20.4

Notes:

[185] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[186] - European region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[187]</sup>
P-value	= 0.005 <sup>[188]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	29.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.7
upper limit	46.1

Notes:

[187] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[188] - European region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 5
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[189]</sup>
P-value	= 0.382 <sup>[190]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	20.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.4
upper limit	55.9

Notes:

[189] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001

[190] - Japanese region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 6
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[191]</sup>
P-value	= 0.087 <sup>[192]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	39

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	69.6

Notes:

[191] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[192] - Japanese region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[193]</sup>
P-value	= 1 <sup>[194]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.7
upper limit	35.7

Notes:

[193] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001

[194] - Japanese region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 8
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[195]</sup>
P-value	= 0.028 <sup>[196]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	51.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.2
upper limit	77

Notes:

[195] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[196] - Japanese region: ACR20 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 9
-----------------------------------	------------------------



Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[197]</sup>
P-value	= 0.175 <sup>[198]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	11.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	27.9

Notes:

[197] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[198] - European region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 11
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[199]</sup>
P-value	= 0.271 <sup>[200]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	24.9

Notes:

[199] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[200] - European region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 10
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[201]</sup>
P-value	= 0.026 <sup>[202]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	17.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	34.1

Notes:

[201] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[202] - European region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 12
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[203]</sup>
P-value	= 0.021 <sup>[204]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	18.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.4
upper limit	36

Notes:

[203] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[204] - European region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 14
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[205]</sup>
P-value	= 0.283 <sup>[206]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	25.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	63.2

Notes:

[205] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[206] - Japanese region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 13
-----------------------------------	-------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[207]</sup>
P-value	= 1 <sup>[208]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	34.8

Notes:

[207] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[208] - Japanese region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 15
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[209]</sup>
P-value	= 0.529 <sup>[210]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35
upper limit	22.7

Notes:

[209] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[210] - Japanese region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 16
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[211]</sup>
P-value	= 0.059 <sup>[212]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	38.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.6
upper limit	71.2

Notes:

[211] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[212] - Japanese region: ACR50 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 17
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[213]</sup>
P-value	= 1 <sup>[214]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	14.2

Notes:

[213] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[214] - European region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 18
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[215]</sup>
P-value	= 0.242 <sup>[216]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.7
upper limit	19.4

Notes:

[215] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[216] - European region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 19
-----------------------------------	-------------------------

Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[217]</sup>
P-value	= 0.41 <sup>[218]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	16.9

Notes:

[217] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[218] - European region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 20
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[219]</sup>
P-value	= 0.03 <sup>[220]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	13.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.7
upper limit	29.5

Notes:

[219] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[220] - European region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 21
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[221]</sup>
P-value	= 0.529 <sup>[222]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-35
upper limit	22.7

Notes:

[221] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[222] - Japanese region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 22
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	141
Analysis specification	Pre-specified
Analysis type	other <sup>[223]</sup>
P-value	= 1 <sup>[224]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.7
upper limit	39.5

Notes:

[223] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[224] - Japanese region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 23
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg) v Mavrilimumab 50 mg
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	other <sup>[225]</sup>
P-value	= 0.529 <sup>[226]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35
upper limit	22.7

Notes:

[225] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[226] - Japanese region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

<b>Statistical analysis title</b>	Statistical Analysis 24
-----------------------------------	-------------------------

Statistical analysis description:

Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	other <sup>[227]</sup>
P-value	= 1 <sup>[228]</sup>
Method	Fisher exact
Parameter estimate	Percent difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.5
upper limit	22.6

Notes:

[227] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

[228] - Japanese region: ACR70 - p-value was calculated using a two-tailed Fisher's exact test.

## Secondary: Number of Participants who Achieved ACR Categorical Responses

End point title	Number of Participants who Achieved ACR Categorical Responses
-----------------	---

End point description:

ACR20, ACR50, and ACR70, were defined as  $\geq 20\%$ ,  $\geq 50\%$ , or  $\geq 70\%$  improvement, respectively, in: SJC and TJC and  $\geq 20\%$ ,  $\geq 50\%$ , or  $\geq 70\%$  improvement, respectively, in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. ACR responses were categorized as "No response", "ACR20 but not ACR50", "ACR50 but not ACR70", and "ACR70". The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: participants				
No response	28	21	30	14
ACR20 but not ACR50	10	13	10	17
ACR50 but not ACR70	8	10	5	9
ACR70	2	5	3	7

End point values	Placebo			
------------------	---------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	92			
Units: participants				
No response	58			
ACR20 but not ACR50	23			
ACR50 but not ACR70	6			
ACR70	5			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Continuous ACR (ACRn) Score

End point title	Continuous ACR (ACRn) Score
End point description:	
ACR score - continuous (ACRn) was defined as the minimum of the percentage improvement in TJC, SJC and the median of the percentage improvements in the other five components of the ACR criteria (participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; disability index of the HAQ; and CRP). Total score range was -100 to 100, where negative numbers indicated worsening and positive numbers indicated improvement. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure	
End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	44	47	45	46
Units: units on a scale				
arithmetic mean (standard error)	19.13 ( $\pm$ 5.818)	26.31 ( $\pm$ 5.652)	12.17 ( $\pm$ 5.786)	37.11 ( $\pm$ 5.723)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: units on a scale				
arithmetic mean (standard error)	5.09 ( $\pm$ 4.23)			



## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	other <sup>[229]</sup>
P-value	= 0.051
Method	Repeated measures model
Parameter estimate	Adjusted Mean difference
Point estimate	14.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	28.15
Variability estimate	Standard error of the mean
Dispersion value	7.162

Notes:

[229] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[230]</sup>
P-value	= 0.003
Method	Repeated measures model
Parameter estimate	Adjusted Mean difference
Point estimate	21.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.39
upper limit	35.07
Variability estimate	Standard error of the mean
Dispersion value	7.028

Notes:

[230] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg

Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other <sup>[231]</sup>
P-value	= 0.322
Method	Repeated measures model
Parameter estimate	Adjusted Mean difference
Point estimate	7.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.96
upper limit	21.14
Variability estimate	Standard error of the mean
Dispersion value	7.136

Notes:

[231] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
Statistical analysis description:	
Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[232]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted Mean difference
Point estimate	32.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.08
upper limit	45.98
Variability estimate	Standard error of the mean
Dispersion value	7.085

Notes:

[232] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

## Secondary: Continuous ACR (ACRn) Score by Region

End point title	Continuous ACR (ACRn) Score by Region
End point description:	
ACR score - continuous (ACRn) was defined as the minimum of the percentage improvement in TJC, SJC and the median of the percentage improvements in the other five components of the ACR criteria (participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; disability index of the HAQ; and CRP). Total score range was -100 to 100, where negative numbers indicated worsening and positive numbers indicated improvement. Data for European and Japanese regions were reported. The ITT population (Six participants were excluded from the ITT population for data integrity issues). Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.	
End point type	Secondary

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	44	47	45	46
Units: units on a scale				
arithmetic mean (standard error)				
European region (n=69,36,39,38,38)	19.18 (± 6.489)	24.12 (± 6.263)	12.53 (± 6.356)	36.06 (± 6.356)
Japanese region (n=15,8,8,7,8)	18.09 (± 13.843)	37.22 (± 13.843)	10.2 (± 14.799)	42.09 (± 13.843)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: units on a scale				
arithmetic mean (standard error)				
European region (n=69,36,39,38,38)	4.71 (± 4.689)			
Japanese region (n=15,8,8,7,8)	5.99 (± 10.06)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis reported for European region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	other <sup>[233]</sup>
P-value	= 0.071
Method	Repeated measures model
Parameter estimate	Adjusted Mean difference
Point estimate	14.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.24
upper limit	30.22
Variability estimate	Standard error of the mean
Dispersion value	7.981

Notes:

[233] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Analysis reported for European region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[234]</sup>
P-value	= 0.013
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	19.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.06
upper limit	34.8
Variability estimate	Standard error of the mean
Dispersion value	7.798

Notes:

[234] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Analysis reported for European region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other <sup>[235]</sup>
P-value	= 0.32
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	7.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.68
upper limit	23.36
Variability estimate	Standard error of the mean
Dispersion value	7.873

Notes:

[235] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Analysis reported for European region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg

Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[236]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	31.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.85
upper limit	46.89
Variability estimate	Standard error of the mean
Dispersion value	7.873

Notes:

[236] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for Japanese region. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	other <sup>[237]</sup>
P-value	= 0.483
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	12.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.41
upper limit	46.64
Variability estimate	Standard error of the mean
Dispersion value	17.089

Notes:

[237] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported for Japanese region. Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[238]</sup>
P-value	= 0.075
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	31.24

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.28
upper limit	65.77
Variability estimate	Standard error of the mean
Dispersion value	17.089

Notes:

[238] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
Statistical analysis description:	
Analysis reported for Japanese region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other <sup>[239]</sup>
P-value	= 0.815
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	4.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.89
upper limit	40.32
Variability estimate	Standard error of the mean
Dispersion value	17.872

Notes:

[239] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
Statistical analysis description:	
Analysis reported for Japanese region. Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[240]</sup>
P-value	= 0.041
Method	Repeated measures model
Parameter estimate	Adjusted mean difference
Point estimate	36.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.58
upper limit	70.63
Variability estimate	Standard error of the mean
Dispersion value	17.089

Notes:

[240] - 95 percent (%) unconditional exact confidence interval calculated using the method of Agresti and Min, 2001.

## Secondary: Swollen and Tender Joint Count

End point title	Swollen and Tender Joint Count
-----------------	--------------------------------

End point description:

Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling = 1. Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: joints				
arithmetic mean (standard deviation)				
Swollen joint count	8 (± 8.4)	5.4 (± 6.8)	5.8 (± 7.4)	4.4 (± 4.3)
Tender joint count	11.2 (± 10.9)	9.8 (± 10.1)	13.9 (± 11.8)	9.1 (± 8.8)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: joints				
arithmetic mean (standard deviation)				
Swollen joint count	9.2 (± 10)			
Tender joint count	14.8 (± 13.1)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Swollen and Tender Joint Count by Region

End point title	Swollen and Tender Joint Count by Region
-----------------	--

End point description:

Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling = 1. Number of tender joints was determined by examining 68 joints and identified the joints

that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1. Data for the European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: joints				
arithmetic mean (standard deviation)				
European: Swollen joint count (n=69,36,39,39,38)	8 (± 8.2)	5.6 (± 7.2)	6.4 (± 8)	4.2 (± 4.4)
Japanese: Swollen joint count (n=16,9,8,9,8)	7.8 (± 9.5)	4.6 (± 4.1)	3.1 (± 2.9)	4.9 (± 4.3)
European: Tender joint count (n=69,36,39,39,38)	11 (± 11.4)	11.2 (± 10.5)	14.8 (± 12)	9.9 (± 9)
Japanese: Tender joint count (n=16,9,8,9,8)	12.1 (± 9.1)	2.8 (± 2.4)	9.6 (± 10.1)	5.5 (± 7.2)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: joints				
arithmetic mean (standard deviation)				
European: Swollen joint count (n=69,36,39,39,38)	9.6 (± 10.4)			
Japanese: Swollen joint count (n=16,9,8,9,8)	7.6 (± 8)			
European: Tender joint count (n=69,36,39,39,38)	15.9 (± 13.1)			
Japanese: Tender joint count (n=16,9,8,9,8)	9.6 (± 11.9)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Physician Global Assessment of Disease Activity Score

End point title	Physician Global Assessment of Disease Activity Score
-----------------	---



End point description:

Physician Global Assessment of Arthritis was measured on a 0 to 10 centimeter (cm) Visual Analogue Scale (VAS), where 0 cm = very good and 10 cm = very bad. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: cm				
arithmetic mean (standard deviation)	3.3 (± 2.16)	3.13 (± 1.8)	3.45 (± 1.97)	2.95 (± 1.7)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: cm				
arithmetic mean (standard deviation)	3.82 (± 2.05)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Physician Global Assessment of Disease Activity Score by Region

End point title	Physician Global Assessment of Disease Activity Score by Region
-----------------	---

End point description:

Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad. Data for European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: cm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	3.29 (± 2.21)	3.2 (± 1.79)	3.54 (± 1.98)	3.12 (± 1.74)
Japanese region (n=16,9,8,9,8)	3.37 (± 2.05)	2.79 (± 1.91)	3.08 (± 2.03)	2.18 (± 1.37)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: cm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	3.93 (± 2.06)			
Japanese region (n=16,9,8,9,8)	3.31 (± 1.99)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Patient Global Assessment of Disease Activity Score

End point title	Patient Global Assessment of Disease Activity Score
-----------------	---

End point description:

Participants responded to a question, "Considering all the ways your arthritis affects you, how are you feeling today?" by using a 0 - 100 millimeter (mm) VAS, where 0 = very well and 100 = very poorly. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm				
arithmetic mean (standard deviation)	40 (± 22.8)	37.2 (± 21.1)	41.1 (± 23.2)	35.5 (± 19.3)

<b>End point values</b>	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm				
arithmetic mean (standard deviation)	45.1 (± 24.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Patient Global Assessment of Disease Activity Score by Region

End point title	Patient Global Assessment of Disease Activity Score by Region
-----------------	---

End point description:

Participants responded to a question, "Considering all the ways your arthritis affects you, how are you feeling today?" by using a 0 - 100 mm VAS, where 0 = very well and 100 = very poorly. Data for European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

<b>End point values</b>	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	39.5 (± 22.2)	39 (± 20.6)	42.5 (± 23.6)	37.3 (± 19.2)
Japanese region (n=16,9,8,9,8)	41.9 (± 26.5)	28.8 (± 22.7)	35 (± 21.4)	26.9 (± 18.7)

<b>End point values</b>	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	45.9 (± 23.8)			
Japanese region (n=16,9,8,9,8)	41.5 (± 26.2)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Patient Pain Assessment Score

End point title	Patient Pain Assessment Score
-----------------	-------------------------------

End point description:

Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm				
arithmetic mean (standard deviation)	38.7 (± 24.1)	38.1 (± 24.2)	40.1 (± 24.2)	34.4 (± 21.6)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm				
arithmetic mean (standard deviation)	44.5 (± 24.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Patient Pain Assessment Score by Region

End point title	Patient Pain Assessment Score by Region
-----------------	---

End point description:

Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain. Data for European and Japanese regions were reported. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	38.1 (± 24.1)	39.1 (± 24)	41.4 (± 24.4)	36 (± 22)
Japanese region (n=16,9,8,9,8)	41.1 (± 25.5)	33.3 (± 26.1)	34.1 (± 23.6)	27 (± 19.4)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	44.9 (± 24.4)			
Japanese region (n=16,9,8,9,8)	42.6 (± 27.8)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Health Assessments Questionnaire-Disability Index (HAQ-DI) Score

End point title	Health Assessments Questionnaire-Disability Index (HAQ-DI) Score
-----------------	--

End point description:

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The ITT population included all randomized participants. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: units on a scale				
arithmetic mean (standard deviation)	1.02 ( $\pm$ 0.51)	1.02 ( $\pm$ 0.64)	1.1 ( $\pm$ 0.61)	0.95 ( $\pm$ 0.59)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: units on a scale				
arithmetic mean (standard deviation)	1.19 ( $\pm$ 0.68)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Health Assessments Questionnaire-Disability Index (HAQ-DI) Score by Region

End point title	Health Assessments Questionnaire-Disability Index (HAQ-DI) Score by Region
-----------------	---

End point description:

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Data for European and Japanese regions were reported. The ITT population (Six participants were excluded from the ITT population for data integrity issues). Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: units on a scale				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	1.1 ( $\pm$ 0.47)	1.05 ( $\pm$ 0.67)	1.16 ( $\pm$ 0.63)	1.03 ( $\pm$ 0.56)
Japanese region (n=16,9,8,9,8)	0.72 ( $\pm$ 0.61)	0.91 ( $\pm$ 0.53)	0.82 ( $\pm$ 0.44)	0.56 ( $\pm$ 0.6)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: units on a scale				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	1.22 (± 0.65)			
Japanese region (n=16,9,8,9,8)	1.09 (± 0.82)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Health Assessments Questionnaire (HAQ) Pain Score

End point title	Health Assessments Questionnaire (HAQ) Pain Score
End point description:	
Participants were asked to assess the severity of pain in the past week on a 100 VAS with 0 being no pain and 100 being severe pain. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.	
End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: units on a scale				
arithmetic mean (standard deviation)	40.9 (± 23.5)	39 (± 25)	42.6 (± 23.5)	35 (± 20.8)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: units on a scale				
arithmetic mean (standard deviation)	46.3 (± 24.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Health Assessments Questionnaire (HAQ) Pain Score by Region

End point title	Health Assessments Questionnaire (HAQ) Pain Score by Region
-----------------	---

End point description:

Participants were asked to assess the severity of pain in the past week on a 100 VAS with 0 being no pain and 100 being severe pain. Data for European and Japanese regions were reported. The ITT population included all randomized participants. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: units on a scale				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	40.3 (± 23.6)	40.6 (± 24.8)	43.8 (± 23.8)	36.5 (± 21.1)
Japanese region (n=16,9,8,9,8)	43.1 (± 24.5)	31 (± 26.1)	37.3 (± 22.9)	28.3 (± 19.1)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: units on a scale				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	47 (± 23.9)			
Japanese region (n=16,9,8,9,8)	43.1 (± 26.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Concentration of C-Reactive Protein (CRP)

End point title	Serum Concentration of C-Reactive Protein (CRP)
-----------------	---

End point description:

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants



analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	46	48	46
Units: mg/L				
arithmetic mean (standard deviation)	9.62 ( $\pm$ 4.15)	9.35 ( $\pm$ 3.92)	5.71 ( $\pm$ 2.97)	6.12 ( $\pm$ 2.9)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mg/L				
arithmetic mean (standard deviation)	11.49 ( $\pm$ 4.67)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[241]</sup>
P-value	= 0.663
Method	Repeated measures model
Parameter estimate	Adjusted GM ratio to Baseline
Point estimate	1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.52

Notes:

[241] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Type 2
----------------------------	--------------------

Statistical analysis description:

Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose

escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[242]</sup>
P-value	= 0.497
Method	Repeated measures model
Parameter estimate	Adjusted GM ratio to Baseline
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.25

Notes:

[242] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[243]</sup>
P-value	= 0.03
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	0.96

Notes:

[243] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[244]</sup>
P-value	= 0.003
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	0.84

Notes:

[244] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Serum Concentration of C-Reactive Protein (CRP) by Region

End point title	Serum Concentration of C-Reactive Protein (CRP) by Region
-----------------	---

End point description:

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Data for European and Japanese regions were reported. The ITT population included all randomized participants. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	46	48	46
Units: mg/L				
arithmetic mean (standard deviation)				
European region (n=69,36,38,39,38)	8.86 (± 13.1)	10.24 (± 16.68)	6.5 (± 7.6)	5.84 (± 9.68)
Japanese region (n=16,9,8,9,8)	12.67 (± 18.47)	5.13 (± 6.83)	2.28 (± 1.92)	7.44 (± 12.26)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mg/L				
arithmetic mean (standard deviation)				
European region (n=69,36,38,39,38)	11.89 (± 18.57)			
Japanese region (n=16,9,8,9,8)	9.75 (± 11.93)			

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
European region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[245]</sup>
P-value	= 0.667
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.6

Notes:

[245] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
European region:Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[246]</sup>
P-value	= 0.966
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.47

Notes:

[246] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
European region:Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg

Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[247]</sup>
P-value	= 0.282
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.19

Notes:

[247] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

European region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[248]</sup>
P-value	= 0.018
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	0.92

Notes:

[248] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[249]</sup>
P-value	= 0.873
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.06

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	2.26

Notes:

[249] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[250]</sup>
P-value	= 0.093
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.51

Confidence interval

level	95 %
sides	2-sided
lower limit	0.23
upper limit	1.12

Notes:

[250] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[251]</sup>
P-value	= 0.006
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.34

Confidence interval

level	95 %
sides	2-sided
lower limit	0.16
upper limit	0.73

Notes:

[251] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

# Statistical analysis description:

Japanese region: Analysis reported of CRP ratio to baseline as Geometric Mean(GM). Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[252]</sup>
P-value	= 0.072
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.22
upper limit	1.07

## Notes:

[252] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Serum Concentration of Erythrocyte Sedimentation Rate (ESR)

End point title	Serum Concentration of Erythrocyte Sedimentation Rate (ESR)
End point description:	
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.	
End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm/hr				
arithmetic mean (standard deviation)	31.3 (± 19)	34.1 (± 23.6)	29.7 (± 19.1)	23.6 (± 14.6)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm/hr				
arithmetic mean (standard deviation)	34.4 (± 26.5)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Analysis reported of ESR ratio to baseline as Geometric Mean (GM). Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[253]</sup>
P-value	= 0.81
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.2

Notes:

[253] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	other <sup>[254]</sup>
P-value	= 0.112
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.04

Notes:

[254] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 50 mg



Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[255]</sup>
P-value	= 0.01
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	0.94

Notes:

[255] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[256]</sup>
P-value	= 0.002
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	0.88

Notes:

[256] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Serum Concentration of Erythrocyte Sedimentation Rate (ESR) by Region

End point title	Serum Concentration of Erythrocyte Sedimentation Rate (ESR) by Region
-----------------	---

End point description:

ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Data for European and Japanese regions were reported. The ITT population included all randomized participants. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for this measure for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	47	48	46
Units: mm/hr				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	30.3 (± 18.3)	33.2 (± 23.9)	32.7 (± 19)	23.1 (± 14.3)
Japanese region (n=16,9,8,9,8)	35 (± 22.5)	38.8 (± 22.6)	16.3 (± 13.6)	25.9 (± 16.7)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: mm/hr				
arithmetic mean (standard deviation)				
European region (n=69,36,39,39,38)	33.9 (± 27.8)			
Japanese region (n=16,9,8,9,8)	36.6 (± 20.8)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
European region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[257]</sup>
P-value	= 0.897
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.27

Notes:

[257] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
European region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg

Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	other <sup>[258]</sup>
P-value	= 0.217
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.09

Notes:

[258] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

European region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[259]</sup>
P-value	= 0.408
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.14

Notes:

[259] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

European region:Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[260]</sup>
P-value	= 0.009
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.74

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	0.93

Notes:

[260] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 5
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[261]</sup>
P-value	= 0.474
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.83

Confidence interval

level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.41

Notes:

[261] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Japanese region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	other <sup>[262]</sup>
P-value	= 0.352
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.77

Confidence interval

level	95 %
sides	2-sided
lower limit	0.44
upper limit	1.34

Notes:

[262] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 7
-----------------------------------	------------------------

**Statistical analysis description:**

Japanese region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[263]</sup>
P-value	< 0.001
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	0.58

**Notes:**

[263] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 8
-----------------------------------	------------------------

**Statistical analysis description:**

Japanese region: Analysis reported of ESR ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[264]</sup>
P-value	= 0.098
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	1.09

**Notes:**

[264] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

**Secondary: Serum Concentration of Rheumatoid Factor (RF)**

End point title	Serum Concentration of Rheumatoid Factor (RF)
End point description:	
The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.	
End point type	Secondary
End point timeframe:	
Day 85	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	46	48	46
Units: units per milliliter				
arithmetic mean (standard deviation)	79.62 ( $\pm$ 93.21)	177.84 ( $\pm$ 352.16)	85.15 ( $\pm$ 81.47)	83.26 ( $\pm$ 118.14)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: units per milliliter				
arithmetic mean (standard deviation)	109.82 ( $\pm$ 135.39)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Analysis reported of RF ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[265]</sup>
P-value	= 0.606
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.16

Notes:

[265] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Analysis reported of RF ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.	
Comparison groups	Placebo v Mavrilimumab 30 mg

Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[266]</sup>
P-value	= 0.902
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.13

Notes:

[266] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of RF ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	other <sup>[267]</sup>
P-value	= 0.391
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	1.18

Notes:

[267] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of RF ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	other <sup>[268]</sup>
P-value	= 0.554
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.04

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.16

Notes:

[268] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Serum Concentration of Anti-Citrullinated-Peptide-Antibody (ACPA)

End point title	Serum Concentration of Anti-Citrullinated-Peptide-Antibody (ACPA)
-----------------	---

End point description:

The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 85

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	46	48	45
Units: units per milliliter				
arithmetic mean (standard deviation)	232.22 (± 469.86)	211.77 (± 250.5)	330.82 (± 549.05)	221.18 (± 333.28)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: units per milliliter				
arithmetic mean (standard deviation)	295.9 (± 920.92)			

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Analysis reported of ACPA ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 10 milligram (mg)
-------------------	--



Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other <sup>[269]</sup>
P-value	= 0.286
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	1.12

Notes:

[269] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of ACPA ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 30 mg
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	other <sup>[270]</sup>
P-value	= 0.371
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.15

Notes:

[270] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of ACPA ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 50 mg
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	other <sup>[271]</sup>
P-value	= 0.779
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	1.04

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.33

Notes:

[271] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

<b>Statistical analysis title</b>	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Analysis reported of ACPA ratio to baseline as Geometric Mean(GM).Analysis Type used was dose escalation.

Comparison groups	Placebo v Mavrilimumab 100 mg
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other <sup>[272]</sup>
P-value	= 0.033
Method	Repeated measures model
Parameter estimate	Adjusted GM Ratio to Baseline
Point estimate	0.76

Confidence interval

level	95 %
sides	2-sided
lower limit	0.59
upper limit	0.98

Notes:

[272] - 95 percent (%) unconditional exact confidence interval was calculated using the method of Agresti and Min, 2001.

## Secondary: Number of Participants who had Additional Medications

End point title	Number of Participants who had Additional Medications
-----------------	---

End point description:

Additional medication included concomitant medication (medication used for purposes other than managing rheumatoid arthritis [RA]) and RA medication (for managing RA). Number of participants who used concomitant medication and RA medication was reported by anatomical therapeutic chemical (ATC) classification system. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Day 169

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: participants				
Concomitant: Blood and blood forming agents	47	49	47	45

Concomitant: Alimentary tract and metabolism	25	25	28	23
Concomitant: Cardiovascular system	20	19	12	22
Concomitant: Nervous system	9	9	6	3
Concomitant: Musculo-skeletal system	9	5	8	5
Concomitant: Respiratory system	6	7	5	5
Concomitant: Anti-infective for systemic use	6	6	8	2
Concomitant: Genito-urinary system and sex hormones	6	6	4	4
Concomitant: Systemic hormonal preps	5	4	2	0
Concomitant: Various	5	2	2	4
Concomitant: Dermatologicals	1	5	2	2
Concomitant: Sensory organs	2	3	2	2
Concomitant: Anti-parasitic products	0	0	0	0
RA: Antineoplastic and immunomodulating agents	48	49	48	47
RA: Musculo-skeletal system	35	38	32	31
RA: Systemic hormonal preps	23	21	21	23
RA: Nervous system	0	2	2	1
RA: Alimentary tract and metabolism	2	0	1	0
RA: Dermatologicals	0	0	0	1
RA: Respiratory system	0	0	0	1
RA: Sensory organs	0	0	0	1

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: participants				
Concomitant: Blood and blood forming agents	88			
Concomitant: Alimentary tract and metabolism	45			
Concomitant: Cardiovascular system	30			
Concomitant: Nervous system	14			
Concomitant: Musculo-skeletal system	11			
Concomitant: Respiratory system	11			
Concomitant: Anti-infective for systemic use	10			
Concomitant: Genito-urinary system and sex hormones	4			
Concomitant: Systemic hormonal preps	8			
Concomitant: Various	6			
Concomitant: Dermatologicals	2			
Concomitant: Sensory organs	0			
Concomitant: Anti-parasitic products	1			
RA: Antineoplastic and immunomodulating agents	92			
RA: Musculo-skeletal system	65			
RA: Systemic hormonal preps	47			
RA: Nervous system	4			
RA: Alimentary tract and metabolism	0			

RA: Dermatologicals	1			
RA: Respiratory system	0			
RA: Sensory organs	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Change in Methotrexate (MTX) and Corticosteroid (CST) Dose

End point title	Number of Participants With Change in Methotrexate (MTX) and Corticosteroid (CST) Dose
End point description:	
<p>Participants received MTX at stable and tolerated dose during baseline were categorized as "low dose (&lt;12.5 mg per week [mg/wk])", "medium dose (<math>\geq</math>12.5 - &lt;20 mg/wk)", and "high dose (<math>\geq</math>20 mg/wk)". Participants received oral CST at stable dose during baseline were categorized as "low dose (&lt;5 mg/day)", and "high dose (<math>\geq</math>5 mg/day)". Change in MTX and CST dose from baseline between Day 1-85 and Day 86-169 were categorized as follows: 'Increased', 'no change' and 'decreased'. Participants were counted once with dose increases counted first, followed by no change and then dose decreases. The ITT population analysis set included all randomized participants regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues. Here "n" signifies participants who were evaluable for the specified parameter for each arm, respectively.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Day 1 to 85, Day 86 to 169	

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	49	48	47
Units: participants				
MTX: Low dose (Baseline) (n=92,48,49,48,47)	18	24	29	21
MTX: Medium dose (Baseline) (n=92,48,49,48,47)	25	21	15	25
MTX: High dose (Baseline) (n=92,48,49,48,47)	5	4	4	1
MTX: Increased (Day 1-85) (n=92,48,49,48,47)	0	0	0	0
MTX: No change (Day 1-85) (n=92,48,49,48,47)	46	47	47	45
MTX: Decreased (Day 1-85) (n=92,48,49,48,47)	2	2	1	2
MTX: Increased (Day 86-169) (n=85,45,46,48,45)	3	3	2	1
MTX: No change (Day 86-169) (n=85,45,46,48,45)	42	42	46	44
MTX: Decreased (Day 86-169) (n=85,45,46,48,45)	0	1	0	0
CST: Low dose (Baseline) (n=46,22,21,21,23)	4	2	1	1

CST: High dose (Baseline) (n=46,22,21,21,23)	18	19	20	22
CST: Increased (Day 1-85) (n=46,22,21,21,23)	0	0	0	0
CST: No change (Day 1-85) (n=46,22,21,21,23)	22	21	21	23
CST: Decreased (Day 1-85) (n=46,22,21,21,23)	0	0	0	0
CST: Increased (Day 86-169) (n=46,21,21,22,23)	1	2	2	0
CST: No change (Day 86-169) (n=46,21,21,22,23)	20	19	20	23
CST: Decreased (Day 86-169) (n=46,21,21,22,23)	0	0	0	0

<b>End point values</b>	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: participants				
MTX: Low dose (Baseline) (n=92,48,49,48,47)	39			
MTX: Medium dose (Baseline) (n=92,48,49,48,47)	44			
MTX: High dose (Baseline) (n=92,48,49,48,47)	9			
MTX: Increased (Day 1-85) (n=92,48,49,48,47)	0			
MTX: No change (Day 1-85) (n=92,48,49,48,47)	90			
MTX: Decreased (Day 1-85) (n=92,48,49,48,47)	2			
MTX: Increased (Day 86-169) (n=85,45,46,48,45)	2			
MTX: No change (Day 86-169) (n=85,45,46,48,45)	82			
MTX: Decreased (Day 86-169) (n=85,45,46,48,45)	1			
CST: Low dose (Baseline) (n=46,22,21,21,23)	6			
CST: High dose (Baseline) (n=46,22,21,21,23)	40			
CST: Increased (Day 1-85) (n=46,22,21,21,23)	2			
CST: No change (Day 1-85) (n=46,22,21,21,23)	44			
CST: Decreased (Day 1-85) (n=46,22,21,21,23)	0			
CST: Increased (Day 86-169) (n=46,21,21,22,23)	2			
CST: No change (Day 86-169) (n=46,21,21,22,23)	44			
CST: Decreased (Day 86-169) (n=46,21,21,22,23)	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Observed Serum Concentration (Cmax) for Mavrilimumab After First Dose by Region

End point title	Maximum Observed Serum Concentration (Cmax) for Mavrilimumab After First Dose by Region <sup>[273]</sup>
-----------------	--

End point description:

Data for European and Japanese regions were reported. The pharmacokinetic (PK) population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[273] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	46	49	45	49
Units: nanogram per milliliter (ng/mL)				
geometric mean (standard deviation)				
European region (n=37,41,40,37)	128 (± 1130)	917 (± 796)	6500 (± 3630)	1240 (± 1200)
Japanese region (n=9,8,9,8)	61.3 (± 30.3)	633 (± 388)	4540 (± 927)	1230 (± 652)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Reach Maximum Observed Serum Concentration (Tmax) for Mavrilimumab After First Dose by Region

End point title	Time to Reach Maximum Observed Serum Concentration (Tmax) for Mavrilimumab After First Dose by Region <sup>[274]</sup>
-----------------	--

End point description:

Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[274] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	46	49	45	49
Units: days				
median (full range (min-max))				
European region (n=37,41,40,37)	4 (2 to 7)	3 (2 to 12)	4 (2 to 8)	4 (0 to 8)
Japanese region (n=9,8,9,8)	6 (2 to 8)	7 (3 to 9)	7 (2 to 8)	6 (2 to 9)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area Under the Curve from Time Zero to end of Dosing Interval (AUCtau) for Mavrilimumab After First Dose by Region

End point title	Area Under the Curve from Time Zero to end of Dosing Interval (AUCtau) for Mavrilimumab After First Dose by Region <sup>[275]</sup>
-----------------	---

End point description:

Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[275] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 100 mg	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	46	49	45	49
Units: nanogram*day per milliliter (ng*day/mL)				
geometric mean (standard deviation)				
European region (n=37,41,40,37)	860 (± 8300)	6330 (± 5320)	62500 (± 36600)	10200 (± 10800)
Japanese region (n=9,8,9,8)	504 (± 236)	5820 (± 4300)	45500 (± 12300)	11300 (± 6620)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Observed Serum Concentration (Cmax) for Mavrilimumab

## After Last Dose by Region

End point title	Maximum Observed Serum Concentration (Cmax) for Mavrilimumab After Last Dose by Region <sup>[276]</sup>
-----------------	---

End point description:

Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[276] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	40	45	45
Units: ng/mL				
geometric mean (standard deviation)				
European region (n=33,33,37,37)	137 (± 363)	1030 (± 3150)	2950 (± 2380)	7880 (± 5610)
Japanese region (n=9,7,8,8)	136 (± 156)	1200 (± 727)	3340 (± 1290)	10300 (± 2470)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Reach Maximum Observed Serum Concentration (Tmax) for Mavrilimumab After Last Dose by Region

End point title	Time to Reach Maximum Observed Serum Concentration (Tmax) for Mavrilimumab After Last Dose by Region <sup>[277]</sup>
-----------------	---

End point description:

Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[277] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis



End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	40	45	45
Units: days				
median (full range (min-max))				
European region (n=33,33,37,37)	3 (0 to 6)	3 (0 to 14)	3 (0 to 21)	3 (0 to 14)
Japanese region (n=9,7,8,8)	3 (1 to 5)	3 (1 to 4)	3.5 (0 to 14)	2 (0 to 3)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Curve from Time Zero to end of Dosing Interval (AUCtau) for Mavrilimumab After Last Dose by Region

End point title	Area Under the Curve from Time Zero to end of Dosing Interval (AUCtau) for Mavrilimumab After Last Dose by Region <sup>[278]</sup>
-----------------	--

End point description:

Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[278] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	40	45	45
Units: ng*day/mL				
geometric mean (standard deviation)				
European region (n=33,33,37,37)	1060 (± 2770)	9260 (± 26300)	27900 (± 26700)	80500 (± 64300)
Japanese region (n=9,7,8,8)	915 (± 1020)	12100 (± 9150)	34900 (± 18000)	104000 (± 30300)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Terminal Phase Elimination Half-Life (t<sub>1/2</sub>) for Mavrilimumab After Last Dose by Region

End point title	Terminal Phase Elimination Half-Life (t1/2) for Mavrilimumab After Last Dose by Region <sup>[279]</sup>
-----------------	---

End point description:

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[279] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	40	45	45
Units: days				
arithmetic mean (standard deviation)				
European region (n=33,33,37,37)	5.56 (± 4.08)	4.37 (± 2.88)	6.33 (± 3.07)	6.84 (± 3)
Japanese region (n=9,7,8,8)	6.96 (± 4.61)	7.23 (± 5.67)	7.38 (± 1.65)	7.08 (± 2.19)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Accumulation Ratio for Mavrilimumab After Last Dose by Region

End point title	Accumulation Ratio for Mavrilimumab After Last Dose by Region <sup>[280]</sup>
-----------------	--

End point description:

Accumulation ratio was calculated as ratio of AUCtau after last dose and AUCtau after first dose. Data for European and Japanese regions were reported. The PK population included all participants who received mavrilimumab and for whom serum concentrations of mavrilimumab were available for PK data analyses. Here "N" signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for the specified region for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

PK parameters were measured pre-dose on Days 1, 4, 8, 15, 29, 57, and 85 as well as during follow up on Days 88, 99, 113 and 169

Notes:

[280] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Placebo-treated participants (N=92) were excluded from pharmacokinetic analysis

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Mavrilimumab 50 mg	Mavrilimumab 100 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	40	45	45
Units: ratio				
geometric mean (standard deviation)				
European region (n=33,33,37,37)	1.22 (± 2.97)	1.36 (± 2.23)	2.57 (± 54.1)	1.29 (± 0.932)
Japanese region (n=9,7,8,8)	1.82 (± 1.85)	1.66 (± 0.716)	3.21 (± 3.21)	2.28 (± 0.616)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Mavrilimumab at any Visit

End point title	Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Mavrilimumab at any Visit <sup>[281]</sup>
-----------------	---

End point description:

ADA detection measured by using electrochemiluminescence assays. The immunogenicity population included all participants who received at least 1 dose of CAM-3001 and for whom at least one serum sample for immunogenicity testing was available.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Day 169

Notes:

[281] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The subject analysis sets were created for the safety population due to difference in evaluable participants for the reporting groups and data has been represented accordingly; hence not all the baseline period arms included while reporting end point data.

End point values	Mavrilimumab 10 milligram (mg)	Mavrilimumab 30 mg	Placebo	Mavrilimumab 50 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	48	49	96	49
Units: participants	10	6	3	2

End point values	Mavrilimumab 100mg			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: participants	2			

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From start of the study drug treatment up to Day 169 (Follow-up)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

### Reporting groups

Reporting group title	CAM-3001 10 MG
-----------------------	----------------

Reporting group description:

Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Reporting group title	CAM-3001 30 MG
-----------------------	----------------

Reporting group description:

Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Reporting group title	CAM-3001 50 MG
-----------------------	----------------

Reporting group description:

Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Reporting group title	CAM-3001 100 MG
-----------------------	-----------------

Reporting group description:

Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Reporting group title	PLACEBO
-----------------------	---------

Reporting group description:

Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Serious adverse events	CAM-3001 10 MG	CAM-3001 30 MG	CAM-3001 50 MG
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 48 (4.17%)	2 / 49 (4.08%)	1 / 49 (2.04%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			

subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc disorder			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	CAM-3001 100 MG	PLACEBO	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			

subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Intervertebral disc disorder			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	CAM-3001 10 MG	CAM-3001 30 MG	CAM-3001 50 MG
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 48 (66.67%)	29 / 49 (59.18%)	26 / 49 (53.06%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Venous insufficiency			

subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	1 / 49 (2.04%) 1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	2	0
Injection site papule			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Malaise			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	2
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	1 / 49 (2.04%)
occurrences (all)	0	1	1
Social circumstances			
Family stress			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Breast cyst			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0



Menopausal symptoms subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Metrorrhagia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 3	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Nasal inflammation subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 49 (2.04%) 1	0 / 49 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 49 (2.04%) 1	0 / 49 (0.00%) 0
Psychiatric disorders			
Acute stress disorder subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 49 (2.04%) 1	0 / 49 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Investigations			

Alanine aminotransferase increased			
subjects affected / exposed	1 / 48 (2.08%)	2 / 49 (4.08%)	1 / 49 (2.04%)
occurrences (all)	1	2	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Blood cholesterol increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Blood triglycerides increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Blood urine present			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Carbon monoxide diffusing capacity decreased			
subjects affected / exposed	10 / 48 (20.83%)	3 / 49 (6.12%)	5 / 49 (10.20%)
occurrences (all)	13	3	5
Eosinophil count increased			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Forced expiratory volume decreased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Nitrite urine			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Spirometry abnormal			

subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	3 / 48 (6.25%)	1 / 49 (2.04%)	1 / 49 (2.04%)
occurrences (all)	4	2	1
Urine albumin/creatinine ratio increased			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Arthropod bite			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Excoriation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Joint injury			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Toxicity to various agents			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Cardiac disorders			
Aortic valve incompetence			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Arteriosclerosis coronary artery			

subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Cardiac hypertrophy			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block first degree			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Palpitations			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Head discomfort			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	1	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 48 (4.17%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	2	0	1
Eosinophilia			

subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Monocytopenia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Monocytosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 48 (2.08%)	2 / 49 (4.08%)	2 / 49 (4.08%)
occurrences (all)	2	2	2
Thrombocytopenia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Thrombocytosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Scleritis			

subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 49 (0.00%) 0	0 / 49 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Dry mouth			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	1 / 48 (2.08%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	1	1	0
Nausea			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Tooth malformation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Eczema asteatotic			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Haemorrhage subcutaneous			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Papule			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Skin exfoliation			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	1	0	1
Spider naevus			

subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Urticaria papular			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Ketonuria			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Proteinuria			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Bursitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Neck pain			



subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Osteoporosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Rheumatoid arthritis			
subjects affected / exposed	3 / 48 (6.25%)	2 / 49 (4.08%)	3 / 49 (6.12%)
occurrences (all)	3	2	5
Rotator cuff syndrome			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Acute tonsillitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Adenoiditis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	1 / 48 (2.08%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	1	1	0
Bronchitis viral			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

Enteritis infectious			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Erysipelas			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Gastrointestinal viral infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Genitourinary tract infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Herpangina			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Infected bites			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	2 / 48 (4.17%)	1 / 49 (2.04%)	2 / 49 (4.08%)
occurrences (all)	2	1	2
Nasopharyngitis			
subjects affected / exposed	2 / 48 (4.17%)	5 / 49 (10.20%)	3 / 49 (6.12%)
occurrences (all)	2	7	3
Oral herpes			
subjects affected / exposed	1 / 48 (2.08%)	2 / 49 (4.08%)	0 / 49 (0.00%)
occurrences (all)	1	2	0
Pharyngitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	2 / 49 (4.08%)
occurrences (all)	0	1	2

Pyelonephritis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 49 (2.04%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Streptococcal infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Tinea pedis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Tinea versicolour			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	2 / 48 (4.17%)	1 / 49 (2.04%)	2 / 49 (4.08%)
occurrences (all)	2	1	2
Urinary tract infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	1 / 48 (2.08%)	1 / 49 (2.04%)	1 / 49 (2.04%)
occurrences (all)	1	1	2
Hyperglycaemia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 49 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	CAM-3001 100 MG	PLACEBO	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 48 (58.33%)	46 / 96 (47.92%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 48 (0.00%)	2 / 96 (2.08%)	
occurrences (all)	0	2	
Venous insufficiency			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Injection site pain			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	2	0	

Injection site papule subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Malaise subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 96 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Social circumstances Family stress subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 2	
Reproductive system and breast disorders Amenorrhoea subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 96 (0.00%) 0	
Breast cyst subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Menopausal symptoms subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 96 (0.00%) 0	
Metrorrhagia subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	3 / 96 (3.13%) 3	
Dyspnoea			

subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Epistaxis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Nasal inflammation			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Oropharyngeal pain			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	2	
Psychiatric disorders			
Acute stress disorder			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Depression			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Sleep disorder			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Blood cholesterol increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Blood triglycerides increased			

subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Blood urine present			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Carbon monoxide diffusing capacity decreased			
subjects affected / exposed	5 / 48 (10.42%)	5 / 96 (5.21%)	
occurrences (all)	6	6	
Eosinophil count increased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Forced expiratory volume decreased			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Hepatic enzyme increased			
subjects affected / exposed	1 / 48 (2.08%)	2 / 96 (2.08%)	
occurrences (all)	1	2	
Nitrite urine			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Spirometry abnormal			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Transaminases increased			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Urine albumin/creatinine ratio increased			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Injury, poisoning and procedural complications			

Ankle fracture			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Arthropod bite			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Contusion			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Excoriation			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Foot fracture			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Joint injury			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Toxicity to various agents			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Cardiac disorders			
Aortic valve incompetence			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Cardiac hypertrophy			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Ventricular extrasystoles			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Atrioventricular block first degree			



subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Palpitations			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Supraventricular extrasystoles			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Head discomfort			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Headache			
subjects affected / exposed	1 / 48 (2.08%)	1 / 96 (1.04%)	
occurrences (all)	1	1	
Hypoaesthesia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 48 (2.08%)	5 / 96 (5.21%)	
occurrences (all)	1	5	
Eosinophilia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Leukopenia			
subjects affected / exposed	0 / 48 (0.00%)	2 / 96 (2.08%)	
occurrences (all)	0	4	
Lymphopenia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Monocytopenia			

subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	2 / 96 (2.08%) 2	
Monocytosis subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Neutropenia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 96 (1.04%) 3	
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Ear and labyrinth disorders Ear discomfort subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Vertigo subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1	
Eye disorders Dry eye subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Scleritis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 96 (0.00%) 0	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	1 / 96 (1.04%) 1	
Dry mouth subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0	
Flatulence			

subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Gastritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Abdominal pain upper			
subjects affected / exposed	1 / 48 (2.08%)	1 / 96 (1.04%)	
occurrences (all)	3	1	
Enterocolitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Tooth malformation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Toothache			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Dermatitis			

subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	3	
Eczema			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Eczema asteatotic			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Haemorrhage subcutaneous			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Papule			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 48 (0.00%)	2 / 96 (2.08%)	
occurrences (all)	0	2	
Rash maculo-papular			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Skin exfoliation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Spider naevus			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Urticaria			
subjects affected / exposed	2 / 48 (4.17%)	0 / 96 (0.00%)	
occurrences (all)	2	0	
Urticaria papular			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Ketonuria			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Proteinuria			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Bursitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Muscle spasms			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Musculoskeletal pain			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Neck pain			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Osteoarthritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Osteoporosis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Rheumatoid arthritis			

subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	2	
Rotator cuff syndrome			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Spinal osteoarthritis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Infections and infestations			
Acute tonsillitis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Adenoiditis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Bronchitis			
subjects affected / exposed	2 / 48 (4.17%)	1 / 96 (1.04%)	
occurrences (all)	2	1	
Bronchitis viral			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Cellulitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Cystitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Enteritis infectious			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Erysipelas			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	

Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Genitourinary tract infection subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Herpangina subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Herpes zoster subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 96 (1.04%) 1
Infected bites subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Influenza subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	5 / 48 (10.42%) 5	5 / 96 (5.21%) 5
Oral herpes subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 96 (1.04%) 1
Pyelonephritis subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 96 (1.04%) 1
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 96 (0.00%) 0

Rhinitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Sinusitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Streptococcal infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Tinea pedis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Tinea versicolour			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Tonsillitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 96 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 48 (4.17%)	4 / 96 (4.17%)	
occurrences (all)	2	5	
Urinary tract infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Viral infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	
Glucose tolerance impaired			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Hypercholesterolaemia			



subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Hyperglycaemia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 96 (1.04%)	
occurrences (all)	0	1	
Hyperuricaemia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 96 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 March 2010	The number of sites and participants were increased and dose escalation process in Japan was described.-Inclusion criterion modified.-A description of unblinding process for analysis of primary endpoint was added to protocol.-Pulmonary functional test (PFTs) and DLCO were allowed to be tested day before dosing.-If screening PFTs were performed within 14 days of dosing on Day 1, then a repeat of PFT was not required.-A description of a potential analysis of primary endpoint was added.-Abnormal laboratory test data were to be reported as an adverse event (AE),the assessment of relationship of AEs as related or not related and the description of overdose and pregnancy were modified.-The language describing the DAS28 requirements was clarified to state that participants were required to have at least moderately active disease as defined by DAS28 $\geq 3.2$ at screening and Day 1 to be included in study.
11 October 2010	Study blind was amended.
04 April 2011	Study blind was amended. – Sponsor was allowed to discontinue dosing. - Study Stopping criteria was modified as: any other safety finding assessed as related to investigational product that, in the opinion of the sponsor, contraindicates further dosing of study participants, was added to the study-stopping criteria. - Sections describing hepatic function abnormality and the recoding and reporting of such events were added to the protocol.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/23234647>